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A B S T R A C T
Background
In areas where vitamin A deficiency (VAD) is a public health concern, the maternal dietary intake of vitamin A may be not sufficient to
meet either the maternal nutritional requirements, or those of the breastfed infant, due the low retinol concentrations in breast milk.
Objectives
To evaluate the effects of vitamin A supplementation for postpartum women on maternal and infant health.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (8 February 2016), LILACS (1982 to December 2015),
Web of Science (1945 to December 2015), and the reference lists of retrieved studies.
Selection criteria
Randomised controlled trials (RCTs) or cluster-randomised trials that assessed the effects of vitamin A supplementation for postpartum
women on maternal and infant health (morbidity, mortality and vitamin A nutritional status).
Data collection and analysis
Two review authors independently assessed trials for inclusion, conducted data extraction, assessed risk of bias and checked for accuracy.
We assessed the quality of the evidence using the GRADE approach.
Main results
Fourteen trials of mainly low or unclear risk of bias, enrolling 25,758 women and infant pairs were included. The supplementation
schemes included high, single or double doses of vitamin A (200,000 to 400,000 internation units (IU)), or 7.8 mg daily beta-carotene
compared with placebo, no treatment, other (iron); or higher (400,000 IU) versus lower dose (200,000 IU). In all trials, a considerable
proportion of infants were at least partially breastfed until six months.
Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo or no
treatment)
1Vitamin A supplementation for postpartum women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Maternal: We did not find evidence that vitamin A supplementation reduced maternal mortality at 12 months (hazard ratio (HR)
1.01, 95% confidence interval (CI) 0.44 to 2.21; 8577 participants; 1 RCT, moderate-quality evidence). Effects were less certain at six
months (risk ratio (RR) 0.50, 95% CI 0.09 to 2.71; 564 participants; 1 RCT; low-quality evidence). The effect on maternal morbidity
(diarrhoea, respiratory infections, fever) was uncertain because the quality of evidence was very low (50 participants, 1 RCT). We found
insufficient evidence that vitamin A increases abdominal pain (RR 1.28, 95% CI 0.95 to 1.73; 786 participants; 1 RCT; low-quality
evidence).We found low-quality evidence that vitamin A supplementation increased breast milk retinol concentrations by 0.20 µmol/L
at three to three and a half months (mean difference (MD) 0.20 µmol/L, 95% CI 0.08 to 0.31; 837 participants; 6 RCTs).
Infant: We did not find evidence that vitamin A supplementation reduced infant mortality at two to 12 months (RR 1.08, 95% CI
0.77 to 1.52; 6090 participants; 5 RCTs; low-quality evidence). Effects on morbidity (gastroenteritis at three months) was uncertain
(RR 6.03, 95% CI 0.30 to 121.82; 84 participants; 1 RCT; very low-quality evidence). There was low-quality evidence for the effect on
infant adverse outcomes (bulging fontanelle at 24 to 48 hours) (RR 2.00, 95% CI 0.61 to 6.55; 444 participants; 1 RCT).
Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU
Three studies (1312 participants) were included in this comparison. None of the studies assessed maternal mortality,maternal morbidity
or infant mortality. Findings from one study showed that there may be little or no difference in infant morbidity between the doses
(diarrhoea, respiratory illnesses, and febrile illnesses) (312 participants, data not pooled). No firm conclusion could be drawn on the
impact on maternal and infant adverse outcomes (limited data available).The effect on breast milk retinol was also uncertain due to
the small amount of information available.
Authors’ conclusions
There was no evidence of benefit from different doses of vitamin A supplementation for postpartum women on maternal and infant
mortality and morbidity, compared with other doses or placebo. Although maternal breast milk retinol concentrations improved with
supplementation, this did not translate to health benefits for either women or infants. Few studies reported on maternal and infant
mortality and morbidity. Future studies should include these important outcomes.
P L A I N L A N G U A G E S U M M A R Y
Vitamin A supplementation for postpartum women
What is the issue?
Breastfeeding is expected to provide for the infant’s needs in the early months of life. However, if the mother is undernourished herself,
the infant may not receive all the nutrients they need. Vitamin A is important for immunity and helping the infant stay healthy, so if
the mother does not have enough vitamin A intake in her diet, the infant may also not receive enough in the breast milk.
Why is this important?
In areas where vitamin A deficiency is a public health concern, the maternal dietary intake of vitamin A may be not sufficient to meet
either the maternal nutritional requirements, or those of the breastfed infant, due the low concentrations in breast milk. Many studies
have been carried out to address this concern in countries where vitamin A deficiency is common.
What evidence did we find?
We reviewed 14 trials. The evidence in general was found was to be of low quality. These studies involved the mothers being given
vitamin A or not, within the first six weeks after giving birth, or compared a high dose of vitamin A with a low dose. Our review looked
at the overall health of the mothers and their infants, any adverse effects and the levels of retinol, which is a by-product of vitamin A,
in the mother’s breast milk. There was no change in how many mothers or babies died or were unwell. The mothers and their babies
did not experience adverse effects. There was evidence of improved amounts of retinol in breast milk.
What does this mean?
In summary, although extra vitamin A given to the mother may slightly improve the amount of this nutrient in her breast milk, it
probably makes little or no difference to deaths in the mother or baby. It may lead to little or no difference in any adverse effects to the
mother or baby.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin A supplementat ion (200,000 to 400,000 IU) compared to placebo or no treatment in postpartum women
Patient or population: Postpartum women
Setting: Low- and middle-income sett ings (India, Bangladesh, Indonesia, Tanzania, Gambia, Zimbabwe, Kenya, Ghana, Peru and Brazil)
Intervention: Vitamin A supplementat ion (200,000 to 400,000 IU)
Comparison: Placebo or No treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with Placebo or No
treatment
Risk with Vitamin A
supplementation (200
000 to 400 000 IU)
Maternal mortality
follow-up: 12 months
Study populat ion HR 1.01
(0.44 to 2.21)
8577
(1 RCT)
⊕⊕⊕©
MODERATE 1
ZVITAMBO Study
Group: We calculated
HR f rom Kaplan-Meier-
Curve using Cox model.
Ayah 2007: Ef fects on
maternal mortality at 6
months were imprecise
(0.50, 95% CI 0.09 to 2.
71; 6 deaths, N = 564)
3 per 1000 3 per 1000
(1 to 6)
Maternal morbidity (di-
arrhoea, respiratory in-
fect ions, fever)
follow-up: 3 months
Ef fect is uncertain because the quality of evi-
dence available is very low
- 50
(1 RCT)
⊕©©©
VERY LOW 23
Roy 1997; diarrhoea:
27/ 2281 days with vita-
m in A vs 15/ 2281 with
placebo
respiratory infect ions
82/ 2281 days with vita-
m in A vs 125/ 2281 with
placebo
fever: 30/ 2281 days
with vitamin A vs 28/
2281 with placebo; no
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stat ist ical comparison
performed11
Maternal adverse ef -
fects af ter administra-
t ion: abdominal pain
follow-up: 1.25 days
Study populat ion RR 1.28
(0.95 to 1.73)
786
(1 RCT)
⊕⊕©©
LOW 4
Subset of part icipants
f rom the ZVITAMBO
Study Group162 per 1000 207 per 1000
(153 to 279)
Maternal breast m ilk
ret inol concentrat ion
follow-up: mean 3-3.5
months
The mean maternal
breast m ilk ret inol con-
centrat ion ranged f rom
0.44 to 1.82 mcmol/ L
The mean maternal
breast m ilk ret inol con-
centrat ion in the inter-
vent ion group was 0.
2 mcmol/ L higher (0.08
higher to 0.31 higher)
- 837
(6 RCTs)
⊕⊕©©
LOW 56
Ayah
2007; Mart ins 2010;
RETIBETA Project; Roy
1997; Stoltzfus 1993a;
Vinutha 2000
Infant mortality
follow-up: range 2
months to 12 months
Study populat ion RR 1.08
(0.77 to 1.52)
6090
(5 RCTs)
⊕⊕©©
LOW 78
Ayah 2007; Mart ins
2010; Newton 2005;
Venkatarao 1996;
ZVITAMBO Study
Group
20 per 1000 22 per 1000
(16 to 31)
Infant morbidity (gas-
troenterit is)
follow-up: 3 months
Study populat ion RR 6.03
(0.30 to 121.82)
84
(1 RCT)
⊕©©©
VERY LOW 29
Vinutha 2000. There
were zero events for
gastroenterit is in the
control group and so it
was not possible to cal-
culate ant icipated ab-
solute ef fectssee comment see comment
Infant adverse ef fects:
bulging fontanelle
follow-up: range 1 days
to 2 days
Study populat ion RR 2.00
(0.61 to 6.55)
444
(1 RCT)
⊕⊕©©
LOW 10
Ayah 2007
18 per 1000 36 per 1000
(11 to 118)
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io; HR: Hazard rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious imprecision (95% CI includes both appreciable benef it and harm)
2 Downgraded one level due to serious risk of bias (unclear allocat ion sequence generat ion and concealment; part icipants
and personnel not blinded)
3 Downgraded two levels due to very serious imprecision (very small size, N = 50)
4 Downgraded two levels due to very serious imprecision (95% CI includes both appreciable benef it and harm)
5 Downgraded one level due to serious risk of bias (allocat ion sequence generat ion and concealment unclear in three of six
studies)
6 Downgraded one level due to serious inconsistency (I² = 58%)
7 Not downgraded for risk of bias (sensit ivity analysis excluding three trials with unclear allocat ion randomisat ion did not
change ef fect est imate)
8 Downgraded one level due to serious imprecision (95% CI includes both appreciable benef it and harm)
9 Downgraded two levels due to very serious imprecision (very few events, N = 2; 95% CI includes appreciable benef it and
harm)
10 Downgraded two levels due to very serious imprecision (very few events, N = 12; 95% CI includes both appreciable benef it
and harm)
11Numerator: number of cumulat ive days of illness, denominator: number of people-days of follow-up. The number of people-
days has been extracted f rom the original reference.
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B A C K G R O U N D
Description of the condition
Vitamin A functions and sources
Vitamin A is a common term for a set of fat-soluble substances,
such retinol, retinal, retinoic acid, retinyl ester, and pro-vitamin A
carotenoids (Butte 2002; FNB 2000; Tanumihardjo 2011). It has
an essential role in visual and immune systems, maintenance and
proliferation of epithelial cells, growth and physical development,
reproduction and gene expression (FAO/WHO2001; FNB 2000;
Tanumihardjo 2011; WHO 1998), and during all vital stages of
pregnancy and lactation (WHO 1998).
The dietary sources can be divided in pro-vitamin A and pre-
formed vitamin A. Some vegetables such as buriti, carrot, papaya,
pumpkin, and red palm oil are sources of pro-vitamin A (alfa-
and beta-carotene, alfa-cryptoxanthin). Human breast milk, dairy
products (whole milk, yogurt, cheese, and milk cream), egg yolk,
fish oils and liver are sources of pre-formed vitaminA (FAO/WHO
2001; FNB 2000).
Newborns and infants, in many countries, can only meet their vi-
tamin A requirements through breastfeeding (Butte 2002; WHO
1998), which is associated with maternal nutritional status and
food consumption (Butte 2002). Thus, in lactating women with
adequate vitamin A status and intake, their breast milk retinol
concentrations are sufficient to meet the newborns’ and infants’
needs until the sixth month of life (Butte 2002). On the other
hand, in lactating women with vitamin A deficiency (VAD), their
breast milk retinol concentrations can be sub-optimal to meet the
newborns’ and infants’ needs, as well as, to build or preserve hep-
atic reserves of this micronutrient (Butte 2002; WHO 1998).
According to the World Health Organization (WHO) (WHO
2009a), several risk factors increase the overall burden of disease
in low-income countries. The most important of these include in-
fant underweight, low proportion of breastfeeding, and nutrition
deficiencies, including iron, vitamin A and zinc, with these factors
contributing 20% to the disease burden in these areas, especially
of infectious disease.
Vitamin A indicators
Specific indicators of VAD can be considered as biological,
histological, functional and biochemical (Tanumihardjo 2004;
Tanumihardjo 2011), and also in its clinical and subclinical man-
ifestations (subdivided in degrees: severe, moderate and mild)
(WHO 1996). Xerophthalmia, a biological indicator, is a generic
term that comprises all ocular clinical signs of VAD, including
conjunctival xerosis, Bitot’s spots, corneal xerosis, ulceration, ker-
atomalacia, and corneal scars (Wasantwisut 2002; WHO 1996).
Conjunctival impression cytology (CIC), a histological indicator,
is used to assess the morphological changes in the cells on the sur-
face of the eyes in VAD (Congdon 2002; Tanumihardjo 2011).
Night blindness and impaired adaptation to darkness can be
considered as functional indicators (Tanumihardjo 2011; WHO
1996).
Serum retinol concentration (cut-off: < 0.7 µmol/L), breast milk
retinol concentration (cut-off: < 1.05 µmol/L or 0.28 µmol/g
fat), relative dose response (RDR; cut-off: > 20%), and modi-
fied relative dose response (MRDR; cut-off: > 0.06) are VAD bio-
chemical and subclinical indicators (WHO1996). Both RDR and
MRDR are indirect methods to estimate vitamin A hepatic re-
serves (Tanumihardjo 2004; Tanumihardjo 2011).
Vitamin A and adverse effects
According to Rasmussen 1998, the evidence regarding the terato-
genic effects of high amounts of pre-formed vitamin A in women
at the beginning of pregnancy are scarce. Moreover, case-con-
trol and prospective investigations failed to establish an associa-
tion between maternal vitamin A intake with fetal teratogenicity
(Azaïs-Braesco 2000). Thus, only case reports have described a
link between this adverse outcome and the metabolites, such as
trans retinoic acids and 13-cis retinoic acids, until the sixth week
of pregnancy (Rasmussen 1998).
Allen and colleague (Allen 2002) have reviewed the maternal
and infant secondary adverse effects after high doses of vita-
min A supplementation and noted that the possible acute symp-
toms observedwere enhanced cerebrospinal fluid pressure, bulging
fontanelle, headache, fever, nausea, vomiting, diarrhoea, blurred
vision, drowsiness and impaired muscular co-ordination.
Vitamin A and metabolic interactions
Zinc probably plays an important role in many steps of vitamin
A metabolism, such as absorption, transport, mobilisation and
utilisation (Christian 1998; Hess 2005).
According to Christian 1998, who reviewed the interaction be-
tween these micronutrients, zinc deficiency may for example: im-
pair synthesis of chylomicrons and the uptake by the lymphatic
system; reduce the synthesis of retinol-binding protein (RBP) and,
consequently, vitamin A circulation and utilisation; impair the ox-
idation of retinol to retinal, which is crucial for the visual function;
and decrease the synthesis of rhodopsin and rod photosensitivity,
leading to night blindness and impaired adaptation to darkness.
Although these associations have been observed in laboratory ex-
perimental models, cross-sectional and intervention studies in hu-
mans are not conclusive concerning the strength of the metabolic
interaction between zinc and vitamin A, and its public health im-
plications (Christian 1998; Hess 2005).
In South Africa, a trial conducted in children with HIV and non-
HIV, aged six to 24 months, reported no beneficial influence of
vitamin A plus zinc supplementation compared to vitamin A or
multi-micronutrients on growth. However, in a subgroup analysis,
an improvement was noted on reducing the impact of episodes
of diarrhoea on non-HIV children growth (Chhagan 2010). In
Indonesia, an intervention study carried out with pregnant women
reported no positive effect in morbidity, mortality, birth length or
weight after vitaminA plus zinc supplementation (Prawirohartono
2013).
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It is believed that VAD prejudices iron mobilisation, and utilisa-
tion (Hess 2005), but there is disagreement regarding its role in
absorption (Garcia-Casal 1998; Hess 2005; Walczyk 2003). Some
intervention studies in humans were developed with the aim to
assess the effect of vitamin A supplementation on iron and haema-
tological parameters, and most of them have shown a positive im-
pact in pregnant women and schoolchildren regarding anaemia,
especially when vitamin A was combined with iron (Michelazzo
2013).
According to Zimmermann 2006 and Hess 2005, the ways
whereby vitamin A may affect iron status also include influences
on the erythropoietic process, as well as on immune function, and
the consequent reduction of the risk of infection and the associ-
ated anaemia.
Regarding absorption, Garcia-Casal 1998 has suggested that vi-
tamin A and iron form a complex, which enhances its uptake,
but Walczyk 2003 observed no beneficial effect of this vitamin.
Some studies have shown that iron deficiency impairs vitamin A
metabolism (Oliveira 2008a), probably through a decrease in hep-
atic mobilisation and serum retinol concentrations (Jang 2000;
Strube 2002). In Mexico, a trial developed with pre-school chil-
dren pointed out that iron supplementation improved the vitamin
A nutritional status (Muñoz 2000).
Vitamin A deficiency (VAD)
The global distribution of VAD, published by theWHO in 1995,
classified countries by its importance as a public health problem,
based on clinical (ocular manifestations) and subclinical (serum
retinol) indicators. The geographical regions with the highest pro-
portions of VAD were Africa, Asia and Latin America (WHO
1995).
The most recent report of VAD was presented by WHO in 2009,
and included data from 1995 to 2005. According to this docu-
ment, Africa and South-East Asia were the more affected regions.
Although the studies and surveys included to estimate the magni-
tude of the problem used differentmethodologies, it is understood
that the prevalence of xerophthalmia among pre-school children
decreased, but the subclinical VAD (based on low serum retinol
concentration) in pre-school children and pregnant women in-
creased, probably due to improved assessment techniques, and
larger population samples (WHO 2009b). The VAD data from
lactating women were not considered in this report.
Studies carried out around the world suggested that VAD is still
a public health concern in some regions and countries. In South
Asia, the prevalence of subclinical VAD in children under six years
ranged from 28% to 57% (Akhtar 2013). In India, the proportion
was 62% in pre-school children from rural areas (Laxmaiah 2012).
In Bangladesh, the prevalence was 18.5% in pregnant women (Lee
2008) and 37% in lactating women (Ahmed 2003). In South
Africa, the proportions were 21.4% and 49.3% in postpartum
women and their newborns, respectively (van Stuijvenberg 2015).
Regarding Latin American and Caribbean countries, the preva-
lence of subclinical VAD in children under six years was less than
10% in Central America. However, the proportions were 17.4%
and 13.0% in Brazil and Peru, respectively. The prevalence among
women was 12.3% in Brazil and 8.7% in Peru (Cediel 2015).
The ranges in prevalence of breastfeeding, maternal and infant
mortality in countries with VAD are important in the context of
any public health program involving maternal postnatal supple-
mentation with vitamin A that aims to improve infant nutrition,
through improved maternal health.
Breastfeeding prevalences
The global prevalence of exclusive breastfeeding during the first
six months of life is estimated by WHO 2015a as 36%. The low-
and lower-middle-income groups showed the highest proportions,
47% and 33%, respectively.
The prevalences in Asia, Africa, and America vary by the specific
country (WHO 2015a). In Nepal, Bangladesh, and Indonesia,
70%, 64%, and 42% of infants were exclusively breastfed until
the sixth month of life (WHO 2015a). In India, the prevalence
was 46% (WHO 2014). In Tanzania, the proportion was 50%,
followed by Ghana (46%), Gambia (34%), Kenya (32%), and
Zimbabwe (31%) (WHO 2015a). The prevalence was 72% in
Peru (WHO 2015a) and was 40% in Brazil (WHO 2014).
Maternal mortality rates (MMR)
Although there are concerns about the accuracy of maternal mor-
tality estimates, the statistics for 1990 to 2015 presented byWHO
2015b pointed out a 44% overall decrease in the maternal mortal-
ity ratio (MMR), from 385 to 216 deaths per 100,000 live births
in 1990 and 2015, respectively.
In 2015, almost 99% (302,000) of the total maternal deaths oc-
curred indeveloping areas.Considering the regions, approximately
66% (201,000) and 22% (66,000) of these deaths occurred in
Sub-Saharan Africa and Southern Asia, respectively. The MMR
was 546 in Sub-Saharan Africa and there were 176 deaths per
100,000 live births in Southern Asia. Oceania did not account
for a great number of deaths (500), but the MMR was one of the
highest (187) (WHO 2015b).
Even though developing areas presented the highestMMR, the es-
timates are not comparable considering different countries within
geographical regions. In 2015, theMMRwas higher inNepal (258
deaths per 100,000 live births) than in Bangladesh (176), India
(174) or Indonesia (126). The heterogeneity among African coun-
tries is also obvious. In Gambia the MMR was 706, followed by
Kenya (510), Zimbabwe (443), Tanzania (398) and Ghana (319)
(WHO 2015b). This estimate was 13 for both Northern Amer-
ica and Europe (WHO 2015c). In Latin America and Caribbean
countries, the rates are still relatively high (60 and 175, respec-
tively). TheMMRwas 68 in Peru and 44 in Brazil (WHO2015b).
Infant mortality rates (IMR)
Similarly to maternal mortality, the accuracy of infant mortality
estimates is also an important challenge. Even considering this
limitation, the statistics for 1990 to 2015 presented by United
Nations Children’s Fund (UNICEF 2015) described a substantial
progress in reducing the infant mortality ratio (IMR) by 50%,
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from 63 in 1990 to 32 deaths per 1000 live births in 2015.
In 2015, around 98% (4,383,000) of the total infant deaths oc-
curred in developing areas; approximately 46% (2,018,000) and
34% (1,499,000) of these deaths occurred in Sub-Saharan Africa
and Southern Asia, respectively. The IMR was 56 in Sub-Saharan
Africa and there were 41 deaths per 1000 live births in Southern
Asia. Oceania did not account for a considerable number of total
deaths (11,000), nevertheless the IMR was one of the highest (40)
(UNICEF 2015).
Although developing areas presented the highest IMR, the es-
timates are not homogenous considering the different countries
within geographical regions. In 2015, the IMR was higher in In-
dia (38) than in Bangladesh (31), Nepal (29) or Indonesia (23 per
1000 live births). Differences among African countries are also
evident. In the Gambia the MMR was 48, followed by Zimbabwe
(47), Ghana (43), Kenya (36), and Tanzania (35). This estimate
was six and five in Northern America and Europe, respectively.
In Latin America and Caribbean countries, the rate was 15. The
IMR was 15 in Brazil and 13 in Peru (UNICEF 2015).
Description of the intervention
Vitamin A supplements may take a number of forms, for exam-
ple: as Vitamin A, measured in international units (IU) of retinyl
palmitate (3.33 IU or 0.003491 micromol of retinol = 1 micro-
gram or 1 retinol equivalent (RE) (IVACG 2004), in an oil basis
or water-miscible formulation, or as beta-carotene, generally in
gelatinous capsules.
In 1998 and in 2002, WHO, UNICEF and the International
Vitamin A Consultative Group (IVACG) recommended in areas
where VAD was a public health concern, high doses of maternal
vitamin A supplementation until the sixth week postpartum as an
approach to promote women’s and infants’ health and adequate
nutritional status (Ross 2002; WHO 1998). However, the most
recentWHOguideline (WHO2011) that was developed based on
systematic reviews (Gogia 2010;Gogia 2011;Oliveira-Menegozzo
2010 (the initial version of this review)), did not reinforce this pre-
vious recommendation, and highlighted the role of adequate food
consumption in order to promote maternal health and nutritional
status.
The WHO 1998 guideline described some scenarios that consid-
ered safety and frequency of maternal vitamin A supplementation
during the postpartum period in countries where VAD is a public
health concern. For non-lactating women, a high dose of vitamin
A (over 25,000 IU and usually 200,000 IU) during the first four
weeks postpartum could be beneficial. After six weeks, for these
women a maximum dose of 10,000 IU daily should be adminis-
tered. For lactating women, a high dose (200,000 IU) adminis-
tered until 60 days postpartum could be beneficial for them and,
as well as, for their infants through higher breast milk retinol con-
centrations (WHO 1998). In 2002, WHO (Ross 2002) suggested
that two high doses of vitamin A (200,000 IU each), with a min-
imum of 24 hours apart, could be administered to women until
the sixth week postpartum.
The WHO 2011 guideline made recommendations for future re-
search, including the need to evaluate the impact of vitamin A
(200,000 IU), exactly at the sixth week postpartum compared to
early supplementation for lactating women on breast milk retinol
concentrations. Moreover, the metabolic aspects and body distri-
bution (hepatic reserves and secretion through breast milk) after
the administration of the high doses were also cited as priorities
for further studies.
How the intervention might work
Hypothetically, vitamin A supplementation for postpartum
women from populations where VAD is endemic could reduce
maternal and infant mortality and morbidity risks. Moreover, the
intervention could contribute to building vitamin A hepatic re-
serves and promote an adequate nutritional status for both mother
and infant, thus impacting on morbidity and mortality.
Why it is important to do this review
Considering that VAD remains a public health problem in some
countries and regions, intervention studies, public policies and
nutrition programs have assessed and recommended vitamin A
supplementation during the postpartum period with the aim of
improvingmaternal and infant health.Nevertheless, the countries’
and researchers’ practices and agendas are not always in agreement
with the recommendations of international health agencies, like
WHO. Food intake patterns and body composition shifts have
occurred globally over the last decades, a phenomenon known as
’nutrition transition’, including in regions with a reduction of un-
der-nutrition (Haddad 2015) and of VAD (WHO2009b). There-
fore, changes in a population’s overall health status would be ex-
pected over time, thus necessitating constant revisions of food and
nutrition strategies, and justifying the update of this systematic
review of relevant randomised controlled trials regarding maternal
vitamin A supplementation during the six weeks of puerperium,
that is the postpartum period.
Other reviews have considered vitamin A supplementation in
women of childbearing age, during pregnancy and also provided to
the newborn/infant (Gogia 2010; Gogia 2011; McCauley 2015).
We have therefore focused this review on vitamin A supplementa-
tion for postpartum women only. This is an update of the review
originally published in 2010 (Oliveira-Menegozzo 2010).
O B J E C T I V E S
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To evaluate the effects of vitamin A supplementation, alone or
in combination with other micronutrients (e.g. iron, folic acid,
vitamin E) for postpartumwomen, onmaternal and infant health.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials that evaluated the effects
of vitamin A supplementation for postpartum women. Cluster-
randomised trials were eligible for inclusion but none were iden-
tified. Quasi-randomised trials and cross-over studies were not el-
igible for inclusion.
Types of participants
Studies involving postpartum women, breastfeeding or not, from
countries where vitamin A deficiency (VAD) is a concern were
eligible. We did not include studies of women with confirmed
chronic diseases such as HIV, as we considered these studies to be
beyond the scope of this review and have been reviewed elsewhere,
for example, Kongnyuy 2009. Maternal data from studies con-
ducted in areas with a high prevalence of HIV without individual
diagnostics at baseline were not excluded; only the data of HIV-
negative women in studies conducted with both HIV-positive and
HIV-negative women were considered.
Types of interventions
Maternal vitamin A supplementation (beta-carotene or retinyl
palmitate in oil or water-miscible formulation) alone or in combi-
nation with other micronutrients (examples: iron, folic acid, vita-
min E) compared with placebo, no intervention, other micronu-
trient, or a lower dose of vitamin A, commenced at any time dur-
ing the postpartum period, that is, within 24 hours after birth
until the sixth week postpartum were eligible.
Study protocols could include, for example, maternal administra-
tion of high doses (given as a single dose of 200,000; 300,000; or
400,000 IU), or two doses (for a total of 400,000 IU), daily (7.8
mg or 4327 IU) doses, or a combination of higher or lower doses.
Trials that involved continuous daily/weekly supplementation for
women during their reproductive years (pre-pregnancy or during
pregnancy) were not included, as they have been addressed in
another systematic review (McCauley 2015).
In addition to maternal supplementation, some studies also in-
cluded infant vitamin A supplementation. In these cases, only ma-
ternal outcomes were considered for this review, given that out-
comes for infant supplementation have been considered in other
reviews (Gogia 2010; Gogia 2011). However, infant outcomes
were included in our review if they had been measured prior to
commencement of infant supplementation.
Types of outcome measures
We reviewed most outcomes for up to 12 months postpartum,
with the exception of adverse effects close to the time of vitamin
supplementation.
Primary outcomes
Maternal outcomes
1. Mortality.
2. Morbidity (febrile illness, respiratory tract infection,
diarrhoea, anaemia and others).
3. Adverse effects of vitamin A within three days after
receiving supplement.
Infant outcomes
1. Mortality.
2. Morbidity (febrile illness, respiratory tract infection,
diarrhoea, anaemia and others).
3. Adverse effects of vitamin A supplementation within three
days after receiving supplement.
Secondary outcomes
Maternal outcomes
1. Serum retinol concentration.
2. Vitamin A hepatic reserves (MRDR or RDR).
3. Breast milk retinol concentration.
4. VAD (clinical: impaired visual adaptation to darkness,
night blindness, xerophthalmia; and subclinical: abnormal
conjunctival impression cytology (CIC)).
Infant outcomes
1. Serum retinol concentration.
2. Vitamin A hepatic reserves (relative dose response (RDR) or
modified relative dose response (MRDR)).
3. Clinical VAD (clinical: signs of xerophthalmia).
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
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Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (8 Febru-
ary 2016).
The Register is a database containing over 20,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full
search methods used to populate the Pregnancy and Childbirth
Group’s Trials Register including the detailed search strategies for
CENTRAL, MEDLINE, Embase and CINAHL; the list of hand-
searched journals and conference proceedings, and the list of jour-
nals reviewed via the current awareness service, please follow this
link to the editorial information about the Cochrane Pregnancy
and Childbirth Group inTheCochrane Library and select the ‘Spe-
cialized Register ’ section from the options on the left side of the
screen.
Briefly, the Cochrane Pregnancy and Childbirth Group’s Trials
Register is maintained by the Trials Search Co-ordinator and con-
tains trials identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth Group review topic (or topics),
and is then added to the Register. The Trials Search Co-ordina-
tor searches the Register for each review using this topic number
rather than keywords. This results in a more specific search set
which has been fully accounted for in the relevant review sections
(Included, Excluded, Awaiting Classification or Ongoing).
In addition, we searched LILACS - Latin American and Caribbean
Health Sciences by Bireme (1982 to December 2015) and Web
of Science (1945 to December 2015), using the search strategies
detailed in Appendix 1.
For additional searching carried out in previous versions of this
review, see: Oliveira 2008b; Oliveira-Menegozzo 2010.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Oliveira-Menegozzo 2010.
For this current version, the following methods were used for as-
sessing the 691 studies that were identified as a result of the Preg-
nancy and Childbirth Group register updated search (27) and by
the authors additional searches of the LILACS (109) and Web of
Science (555) databases.
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Selection of studies
Two review authors (JMO, RA) independently assessed for inclu-
sion all the potential studies identified as a result of the search
strategy. We resolved any disagreement through discussion or, if
required, we consulted the third review author (CEE). We elected
to only include studies reported in brief abstracts if they provided
sufficient information to allow us to assess risk of bias; if not, such
studies would await further assessment pending publication of the
full study report.
Data extraction and management
For eligible studies identified in this update, two review authors
(JMO, RA) extracted the data using the Pregnancy and Childbirth
standard form.We resolved discrepancies or uncertainties through
discussion or, if required, we consulted the third review author
(CEE).Datawere entered intoReviewManager software (RevMan
2014) and checked for accuracy.
When information regarding any of the above was unclear, we
contacted authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors (JMO, RA) independently assessed risk of bias
for each study included in this update using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Any disagreement or uncertainty was resolved by
discussion or by involving a third assessor (CEE).
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
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(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we planned to
assess the likely magnitude and direction of the bias and whether
we considered it is likely to impact on the findings. We explored
the impact of the level of bias through undertaking sensitivity
analyses - see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
For this update, we assessed the quality of the evidence using
the GRADE approach as outlined in the GRADE Handbook in
order to estimate the quality of the body of evidence relating to
the following outcomes (for the main comparison of vitamin A
supplementation versus control (placebo, no treatment, other)):
1. maternal mortality;
2. maternal morbidity;
3. maternal adverse effects of vitamin A supplementation;
4. breast milk retinol concentration;
5. infant mortality;
6. infant adverse effects of vitamin A supplementation;
7. infant morbidity.
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We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
a ’Summary of findings’ table. A summary of the intervention
effect and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean difference if outcomes were measured in the
same way between trials.We planned to use the standardised mean
difference to combine trials that measured the same outcome, but
used different methods.
Unit of analysis issues
Cluster-randomised trials
We will include cluster-randomised trials in the analyses along
with individually-randomised trials if any are identified in future
updates of this review. We will adjust their sample sizes using
the methods described in the Handbook (Higgins 2011) using an
estimate of the intracluster correlation co-efficient (ICC) derived
from the trial (if possible), from a similar trial or from a study of
a similar population. If we use ICCs from other sources, we will
report this and conduct sensitivity analyses to investigate the effect
of variation in the ICC. If we identify both cluster-randomised
trials and individually-randomised trials, we plan to synthesise the
relevant information. We will consider it reasonable to combine
the results from both if there is little heterogeneity between the
study designs and the interactionbetween the effect of intervention
and the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Cross-over trials are unlikely to be an appropriate design for Preg-
nancy and Childbirth reviews and were therefore not eligible for
inclusion in our review.
Other unit of analysis issues
As trials in Pregnancy and Childbirth may include outcomes for
multiple pregnancies, we planned to collectmaternal outcomedata
once for the women and for infant outcomes on the individual
babies.
Trials with more than two arms
In the original version of the review (Oliveira-Menegozzo 2010),
we didnot specify howwewould deal with trials that reported three
ormore groups. Asmethods have evolved in the intervening period
(seeHiggins 2011, Section 16.5.4), we retained the process that we
had used for the study by Ayah 2007 in the previous version of the
review, but havemade an adjustment to the numbers of events and
total participants in the control group of the RETIBETA Project
in this update.
The study by Ayah 2007 involved four groups: two groups of
women received vitamin A supplementation and their infants re-
ceived either vitaminA or placebo. Similarly, two groups of women
received the placebo and their infants received either supplemental
vitamin A or placebo. The women could only receive either the
treatment or placebo, meaning there were effectively only two ma-
ternal arms: supplementation or placebo. We therefore reported
maternal outcomes from these two groups. As this review did not
include infant supplementation within its scope, we only reported
infant outcomes if the infant had received the placebo. Thewomen
could have received either vitamin A supplementation or placebo.
In this way, we avoided any concerns about double-counting.
By contrast, the RETIBETA Project, which involved a total of
three groups: two groups each using a different form of vitamin A
supplementation (that we reported separately from other studies)
and a control arm. We halved the numbers of events and partici-
pants (rounding up if an uneven number was noted) in the control
arm for dichotomous outcomes. For continuous outcomes, we re-
tained the mean and standard deviation and halved the number of
participants, consistent with one of the options for dealing with
this unit of analysis issue from Higgins 2011 (Section 16.5.4).
We avoided needing to combine data from four arms in the study
reported by Newton 2005, as there was sufficient detail available
to only include the two postpartum supplementation (or placebo)
arms. The other two arms involved supplementation or placebo
during pregnancy, which fell outside the scope of this review.
Dealing with missing data
For included studies, we noted levels of attrition. In future updates
of this review, if more eligible studies are included, we will explore
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the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, analyses were carried out, as far as possible, on an
intention-to-treat basis i.e. we attempted to include all participants
randomised to each group in the analyses. The denominator for
each outcome in each trial was the number randomised minus any
participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either the Tau² was
greater than zero, or there was a low P value (less than 0.10) in
the Chi² test for heterogeneity. Had we identified substantial het-
erogeneity (above 30%), we planned to explore it by pre-specified
subgroup analysis.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary, if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average of the range
of possible treatment effects and we discussed the clinical impli-
cations of treatment effects differing between trials. If the aver-
age treatment effect was not clinically meaningful, we would not
have combined trials. Where we used random-effects analyses, the
results were presented as the average treatment effect with 95%
confidence intervals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses. We considered whether an overall summary
was meaningful, and it was, we used random-effects analysis to
produce it.
We planned to conduct the following subgroup analyses, if suffi-
cient data were available:
1. type of supplement (vitamin A (retinyl palmitate or water-
miscible formulation) or beta-carotene);
2. duration of supplementation (daily, single or double dose);
3. dose of supplement (200,000 to 300,000 IU or 400,000
IU);
4. duration of breastfeeding.
All outcomes were included in the subgroup analysis. It was not
possible to conduct subgroup analysis on duration of breastfeed-
ing, but we will include this in future updates, if data become
available.
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2014). We reported the results of sub-
group analyses quoting the Chi² statistic and P value, and the in-
teraction test I² value.
Sensitivity analysis
We carried out sensitivity analyses to explore the effect of trial
quality assessed by concealment of allocation, high attrition rates,
or both,with poor-quality studies being excluded from the analyses
in order to assess whether this made any difference to the overall
result. We also carried out sensitivity analyses to explore the effect
of vitamin A dosage and formulation.
R E S U L T S
Description of studies
Results of the search
For the updated version of the review, we assessed the eligibil-
ity of 691 studies that were identified as a result of the com-
bined searches from the Pregnancy and Childbirth Group’s regis-
ter updated search (n = 27), LILACS (n = 109) and Web of Sci-
ence (n = 555) databases. After the evaluation, five studies were
considered eligible. Two of the studies were included in the re-
view (Fernandes 2012; Martins 2010). Two were added to Studies
awaiting classification, because only the trial registry information
and abstracts were available, which would not have permitted us
to perform a robust data extraction and ’Risk of bias’ assessment
(Nga 2013; Wang 2012). One was added to Ongoing studies, be-
cause only the trial registry and the protocol were available and
published (Ahmad 2015). See Figure 1.
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Figure 1. Systematic review flow diagram.
Included studies
We included a total of 14 studies that enrolled 25,758 women and
infant pairs residing in low-income settings in India, Bangladesh,
Indonesia, Tanzania, Gambia, Zimbabwe, Kenya, Ghana, Peru
and Brazil, countries in which women in the studies were likely
to have low vitamin A levels and low nutritional status. The
Characteristics of included studies table provides further informa-
tion on these trials. Although all studies reported or implied that
postpartum women breastfed their infants, the available details
made it impractical to perform subgroup or sensitivity analyses by
duration of breastfeeding.
Dosage and duration of vitamin A supplementation
Ten studies (Ayah 2007; Bhaskaram 2000;Martins 2010; Newton
2005; Roy 1997; Stoltzfus 1993a; Venkatarao 1996; Vinutha
2000; WHO/CHD IVASSG; ZVITAMBO Study Group) in-
volved the administration of a single dose of vitamin A in the
form of retinyl palmitate or water-miscible formulation (200,000;
300,000 or 400,000 IU) supplementation for women within the
first days or weeks postpartum. Nine of the trials compared vi-
tamin A supplementation with placebo (Ayah 2007; Bhaskaram
2000;Martins 2010;Newton 2005; RETIBETA Project; Stoltzfus
1993a; Venkatarao 1996; WHO/CHD IVASSG; ZVITAMBO
Study Group). In two studies, women in the control group re-
ceived no intervention (Vinutha 2000) or were given iron supple-
mentation (as were those in that study’s intervention group) (Roy
1997). The RETIBETA Project used a three-group approach of
single postpartumdose of vitaminA (as retinyl palmitate) followed
by placebo for nine months, placebo at enrolment followed by
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daily beta-carotene supplementation for nine months, or placebo
at enrolment and daily for nine months. Three trials compared a
lower dose of vitamin A (200,000 IU) with a higher dose (400,000
IU) (Darboe 2007; Fernandes 2012; Idindili 2007).
The studies reported the dosage in a variety of units: for the pur-
pose of this review, dosages have generally been presented as in-
ternational units (IU), based on the calculation of 3.33 IU or
0.003491 micromol of retinol = 1 microgram or 1 retinol equiv-
alent (RE) (IVACG 2004).
Breastfeeding patterns
Ten of the included studies reported that women breastfed their
infants, with several studies noting that all or most of the infants
were exclusively breastfed (Vinutha 2000 for the duration of the
study, Idindili 2007 for the first month, Martins 2010 most until
three months), and others indicating that all or most of infants
were at least partially breastfed to six months (Bhaskaram 2000;
Fernandes 2012; RETIBETA Project; Roy 1997; Venkatarao
1996; WHO/CHD IVASSG; ZVITAMBO Study Group). All
four studies that did not specify details of breastfeeding provided
strong surrogate evidence to support the likelihood of at least par-
tial breastfeeding. The studies by Ayah 2007 and Darboe 2007 re-
ported breast milk retinol levels at six months postpartum, whilst
the study title, background and/or discussion material suggested
that the reports from Newton 2005 and Stoltzfus 1993a related
to breastfeeding, although the duration or extent cannot be esti-
mated.
Excluded studies
Twenty-six studies were excluded because they used:
1. alternate allocation to intervention or control groups (six
studies: Ala-Houhala 1988; Basu 2003; Bezerra 2009; Garcia
2010; Lima 2012; Tchum 2006);
2. supplementation for women during pregnancy (one study:
Ahmad 2009), long-term supplementation during reproductive
age (three studies: ObaapaVitA; NNIPS-2; West 2011), or after
the first six weeks postpartum (four to 12 months postpartum)
(three studies: Haskell 2013a; Haskell 2013b; Turner 2013);
3. provision of fat (one study: Alam 2010), of vitamin A rich
foods alone (nine studies: Atalhi 2011; Canfield 2001; De Pee
1995; El Hamdouchi 2013; Filteau 1999; Khan 2007; Lietz
2001; Lietz 2006; Ncube 2001), or combined with nutrition
counselling (one study: Swaminathan 2015) rather than vitamin
A supplements;
4. vitamin A supplementation for women who live with HIV
(one study: Humphrey 2006);
5. a study designed to evaluate circulating levels of immune
factors following supplementation or placebo, not maternal or
infant mortality/morbidity (one study: Gossage 2000).
(SeeCharacteristics of excluded studies.)
Risk of bias in included studies
We assessed the overall risk of bias in the 14 included trials as being
low or unclear (Figure 2; Figure 3).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We rated eight studies as being of low risk of selection bias (Ayah
2007; Darboe 2007; Fernandes 2012; Idindili 2007; RETIBETA
Project; Stoltzfus 1993a; WHO/CHD IVASSG; ZVITAMBO
Study Group). In most studies, women and infant pairs were in-
dividually randomised in blocks by a computer random number
generator and allocation schedules were concealed by being held
centrally for the duration of the trial.
The remaining reports from the trials byBhaskaram 2000,Martins
2010, Newton 2005, Roy 1997, Venkatarao 1996, and Vinutha
2000, provided no information about the method of randomisa-
tion and concealment and were therefore rated as being of unclear
risk of selection bias.
Blinding
Blinding of participants and personnel (performance bias)
Formost studies, the vitaminA andplacebo capsuleswere identical
or similar in appearance and/or investigators were not aware of
the allocation code (see ’Risk of bias’ tables in Characteristics of
included studies).
In the study by Idindili 2007, the two different doses of vitamin
A were manufactured by the same company, but it was unclear if
they were identical in appearance and there was not enough detail
to judge whether participants were blinded. In the studies by Roy
1997 and Vinutha 2000, no placebo was used (high risk of bias).
Blinding of outcome assessment (detection bias)
For most studies, allocation codes were kept concealed during
the trial duration, field workers were not aware of the aim of the
trial or were blinded to the arms, or the outcomes assessed were
unlikely to be influenced by blinding (see ’Risk of bias’ tables in
Characteristics of included studies). In the study by Idindili 2007,
there was not enough detail to judge about blinding of outcome
assessment.
Incomplete outcome data
In the Venkatarao 1996 trial, there was a 24.2% overall loss of
follow-up, distributed similarly between the three groups and at-
tributed topost-randomisation exclusions formedical reasons such
as congenital abnormalities or jaundice, migration, and miscella-
neous. In the study by Roy 1997, no losses to follow-up were dis-
cussed, but data from the tables indicate 100% follow-up. In the
Vinutha 2000 clinical trial, the loss of follow-up rate was 22.9%.
In the trial by Bhaskaram 2000, the rates of loss to follow-up were
13%and 54%until three and sixmonths postpartum, respectively.
Ayah 2007 reported a 12.6% loss to follow-up by three and half
months and a 22.9% loss by six and a half months postpartum.
In the trial by Darboe 2007, 89.5% of women and infants were
followed up until 12months. Idindili 2007 reported 19%, 20.5%,
22.8%of loss by three, six, and ninemonths, respectively. Attrition
was 11.3% (in both the vitamin A and placebo groups) for HIV-
negative women (985/9562) in the report from the ZVITAMBO
Study Group. Newton 2005 reported an attrition of 34.6%.
Twenty-three of the total 220 women in the RETIBETA Project
missed one or more visits, resulting in follow-up rates of 98%,
95%, and 92% at three, six, and nine months postpartum, respec-
tively, with data reported for these participants in most outcomes.
The exception was for maternal hepatic stores of vitamin A and
serum retinol concentrations, for which approximately 50% of
women were sampled: the report does not specify why all women
were not tested. The study by Stoltzfus 1993a had a 9% loss to
follow-up in each group by three months and 13% and 5% losses
in the vitamin A and control groups respectively by six months -
however, the reasons for attrition and exclusions were not reported
and ITT analysis was not performed.
Loss of follow-up at nine months for the WHO/CHD IVASSG
study was 783 (17%) in the intervention group and 770 (16%)
in the placebo group. This increased to 25% and 24.5% in the
intervention and control groups respectively by 12 months. Infant
death was the only outcome of interest for this review at this time,
therefore it was recorded in this review for the nine-month follow-
up time, rather than at 12 months. Biochemical markers had been
measured in a subgroup of approximately 100 women and their
infants from each of the three participating countries: the exact
number sampled increased from the first to the second timeframe,
which meant we were unable to determine loss to follow-up from
the report.
In the trial by Fernandes 2012, different losses of follow-up were
reported according to the outcome, however at least 60.45% of
women and infant pairs remained until the end of the study. For
infant serum and breast milk retinol concentrations, the with-
drawals and dropouts were comparable between arms. Regarding
maternal serum retinol concentration and infant illness, the with-
drawals and dropout differences between the arms were almost
10%.
The losses to follow-up were similar in the intervention and con-
trol group in the Martins 2010 study. A high rate of follow-up
(89.39%) until three months postpartum was observed.
Selective reporting
We judged all but one trial to be at high risk of selective reporting
(WHO/CHD IVASSG) as they did not provide detail on clinical
outcomes that would be considered fundamental to a study design;
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for example, only five of the 14 trials reported infant mortality
and only two reported maternal mortality.
Other potential sources of bias
We judged most trials as unclear for risk of other bias, mostly due
to a lack of clarity about any influence of funding bodies or not
having published protocols.
Effects of interventions
See: Summary of findings for the main comparison Vitamin A
supplementation (200,000 to 400,000 IU) compared to placebo
or no treatment in postpartum women
Comparison 1: Supplement (vitamin A as retinyl,
water-miscible or beta-carotene) versus control
(placebo, no treatment)
Primary maternal outcomes
Maternal mortality
Two randomised controlled trials (RCTs) evaluatedmaternal mor-
tality for a total of 9141 women (Ayah 2007; ZVITAMBO Study
Group). The study by Ayah 2007 reported no difference in mater-
nal mortality to six months (risk ratio (RR) 0.50, 95% confidence
interval (CI) 0.09 to 2.71; 564 participants, low-quality evidence),
Analysis 1.1. There were no reported differences in maternal mor-
tality after vitamin A supplementation or placebo inHIV-negative
women followed to 12 months (hazard ratio (HR) 1.01, 95% CI
0.44 to 2.21; 8577 participants; 1 RCT,moderate-quality evidence)
in the ZVITAMBO Study Group. The adjusted HR and CI were
estimated based on the Kaplan-Meier curve reported in the study
using Cox model.
Maternal morbidity
One small study of 50 women (Roy 1997) reported no differences
in cumulative episodes of fever, respiratory tract infection or di-
arrhoea (very low-quality evidence, see Analysis 1.2; Analysis 1.3;
Analysis 1.4).
Adverse effects of vitamin A supplementation
In a subset of 786 women from the ZVITAMBO Study Group,
there was no evidence of differences in adverse effects within 30
hours of supplementation, including abdominal pain (RR 1.28,
95% CI 0.95 to 1.73; 786 participants; 1 RCT; low-quality evi-
dence), vomiting, headache, blurred vision, drowsiness, nausea or
poor appetite following a single dose of 400,000 IU vitamin A or
placebo, Analysis 1.5.
Secondary maternal outcomes
Maternal serum retinol
Five studies reported maternal serum retinol values, measured be-
tween three and ninemonths postpartum. In some studies, women
were evaluated at three to three and a half (Ayah 2007; Martins
2010; RETIBETA Project; Roy 1997; Stoltzfus 1993a), six to
six and a half (RETIBETA Project; Roy 1997; Stoltzfus 1993a),
and nine months postpartum (RETIBETA Project; Roy 1997),
as described in the following analysis: Analysis 1.6; Analysis 1.7;
Analysis 1.8, respectively.
Maternal serum retinol concentrations were enhanced by doses of
between 200,000 to 400,000 IU when measured at three to three
and half months (mean difference (MD) 0.11 µmol/L, 95% CI
0.03 to 0.19; 704 participants; 5 RCTs), but were not enhanced by
the largest single dose (400,000 IU) (MD 0.04 µmol/L, 95% CI -
0.01 to 0.09; 402 participants; 1 RCT), or by the daily postpartum
administration of 7.8 mg beta-carotene dose (MD 0.10 µmol/L,
95% CI -0.14 to 0.34; 54 participants; 1 RCT), Analysis 1.6. In
the subgroup analysis regarding doses of 200,000 to 300,000 IU, a
significant increase was also observed (MD 0.17 µmol/L, 95% CI
0.07 to 0.26; 302 participants; 4 RCTs). There was no evidence
of a subgroup difference by dose as indicated by the subgroup
interaction test (test for subgroup differences: Chi² = 6.41, df = 3
(P = 0.09), I² = 53.2%).
Maternal serum retinol concentrationswere not enhancedby doses
of between 200,000 to 400,000 IU, a single dose (400,000 IU),
or by beta-carotene at a 7.8 mg daily dose when measured at
six to six and half months (MD 0.06, 95% CI -0.06 to 0.18;
533 participants; 4 RCTs; MD -0.02, 95% CI -0.08 to 0.04;
291 participants; 1 RCT; MD 0.05, 95% CI -0.28 to 0.38; 50
participants; 1 RCT; respectively), but were enhanced by doses
between 200,000 to 300,000 (MD 0.13, 95% CI 0.03 to 0.23;
242 participants; 3 RCTs), Analysis 1.7. There was no evidence
of a subgroup difference by dose as indicated by the subgroup
interaction test (test for subgroup differences: Chi² = 6.67, df = 3
(P = 0.08), I² = 55.0%).
Maternal serum retinol concentrations were not enhanced at nine
months by doses of between 200,000 to 300,000 IU or by beta-
carotene at a 7.8 mg daily dose (MD 0.00, 95% CI -0.16 to
0.17; 98 participants; 2 RCTs; MD 0.19, 95% CI -0.08 to 0.46;
51 participants; 1 RCT), Analysis 1.8. There was no evidence
of a subgroup difference by dose as indicated by the subgroup
interaction test (test for subgroup differences: Chi² = 1.34, df = 1
(P = 0.25), I² = 25.6%).
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Vitamin A hepatic reserves
Two studies analysed vitamin A hepatic reserves (reported as rel-
ative dose response (RDR) greater than 20% or modified relative
dose response (MRDR) > 0.06) at three, six, and nine months
postpartum (Analysis 1.9; Analysis 1.10; Analysis 1.11). No im-
provement in the proportion of women with low hepatic reserves
at threemonths, (RR 0.58, 95%CI 0.16 to 2.08; 191 participants;
2 RCTs; I² = 73%), Analysis 1.9, following a single 200,000 to
300,000 IU dose of vitamin A, compared with placebo, neither
at six or nine months postpartum. As the data from studies that
administrated different doses of vitamin A were pooled, we used
a random-effects model because it is not possible to assume that
the results would be similar among the trials.
No differences were reported in the RETIBETA Project for this
outcome within nine months of daily beta-carotene supplemen-
tation and placebo at any times, for example, when measured at
nine months (RR 0.59, 95% CI 0.27 to 1.30; 51 participants),
Analysis 1.11.
Breast milk retinol
Breast milk retinol concentrations were reported in several formats
(retinol concentration, proportion of breast milk retinol < 1.05
µmol/L or < 0.28 µmol/g of fat) in seven studies (Analysis 1.12
to Analysis 1.20). There waslow-quality evidence that vitamin A
supplementation (200,000 to 400,000 IU) was associated with
an increased breast milk retinol concentration at three to three
and a half months (MD 0.20 µmol/L, 95% CI 0.08 to 0.31;
837 participants; 6 RCTs). This association was also observed in
the subgroup analysis with the lower doses (200,000 to 300,000
IU) (MD 0.25 µmol/L, 95% CI 0.12 to 0.37; 415 participants;
5 RCTs; low-quality evidence), Analysis 1.12 (test for subgroup
differences: Chi² = 9.16, df = 3 (P = 0.03), I² = 67.2%), but this
improvement was not sustained by six to six and a half months
postpartum. The subgroup heterogeneity observed in the Analysis
1.12 could be explained by the different effects in the breast milk
retinol concentrations. After sensitive analysis, it was possible to
observe that the sources of heterogeneity were the Ayah 2007
and Stoltzfus 1993a trials. Both of them used the higher doses,
400,000 IU and 300,000 IU, respectively, but theMD breast milk
retinol concentrations between intervention and control group
after supplementation vary substantially: 0.08 µmol/L for Ayah
2007 and 0.63 µmol/L for Stoltzfus 1993a. Moreover, theMD for
the remaining studies were more homogeneous and varied by 0.17
to 0.37 µmol/L. Thus, the random-effects model was applied.
Subgroup heterogeneity was also found in the following analysis:
1.13.1, 1.13.2, 1.14.1, 1.15.1, 1.16.1 and 1.17.1. As the data
from studies that administered different doses of vitamin A were
pooled, we used a random-effects model because it is not possible
to assume that the results would be similar among the trials.
Daily doses of beta-carotene to nine months postpartum did not
improve breast milk retinol at three or six months, but did demon-
strate improvement for this outcome by nine months postpartum
(MD 0.21 µmol/L, 95% CI 0.01 to 0.41, 103 participants; test
for subgroup differences: Chi² = 0.11, df = 1 (P = 0.74), I² = 0%),
Analysis 1.14, in the RETIBETA Project, compared with placebo.
Supplementation with a single dose of vitamin A (200,000 to
300,000 IU) reduced the proportion of women with low retinol
concentration (< 1.05 µmol/L) in breast milk at three months
(average RR 0.56, 95%CI 0.37 to 0.84; 304 participants; 3 RCTs;
heterogeneity -Tau² =0.07, I²= 55%; test for subgroupdifferences:
Chi² = 4.88, df = 1 (P = 0.03), I² = 79.5%), Analysis 1.15, but not
at six months after delivery (RR 0.65; 95% CI 0.22 to 1.94; 241
participants; 2 RCTs; test for subgroup differences: Chi² = 0.20,
df = 1 (P = 0.66), I² = 0%), Analysis 1.16, compared with placebo.
Two studies (RETIBETA Project; WHO/CHD IVASSG) re-
ported the proportion of women with low breast milk retinol lev-
els (< 0.28 µmol/g of fat). Supplementation with a single dose of
vitamin A (200,000 IU) or daily beta-carotene 7.8 mg daily for
nine months did not improve this measure at three, six, and nine
months postpartum (Analysis 1.18; Analysis 1.19; Analysis 1.20).
Although no improvements were noted at three and six months
following daily administration of beta-carotene, an improvement
was noted by nine months (RR 0.76, 95% CI 0.60 to 0.97; 102
participants; test for subgroup differences: Chi² = 0.79, df = 1 (P
= 0.37), I² = 0%) in the RETIBETA Project, Analysis 1.20.
Clinical and subclinical vitamin A deficiency (VAD)
One study, Stoltzfus 1993a, measured abnormal conjunctival im-
pression cytology (CIC) in one or both eyes as the criterion for
VAD. There was no difference in the proportion of women with
abnormal CIC at three or six months postpartum, following sup-
plementation with vitamin A or placebo (RR 1.00, 95% CI 0.55
to 1.80; 148 participants; RR 0.56, 95% CI 0.27 to 1.17; 142
participants), Analysis 1.21; Analysis 1.22.
Primary infant outcomes
Infant mortality
Infant mortality was assessed at different times in each of the five
trials that examined this outcome, ranging from up to twomonths
to up to 12 months (Ayah 2007; Newton 2005; Venkatarao 1996;
ZVITAMBO Study Group, Martins 2010), with no differences
for vitamin A compared with placebo (RR 1.08, 95% CI 0.77 to
1.52; 6090 participants; 5 RCTs; low-quality evidence) (Analysis
1.23). The measure of overall effect did not change meaningfully
when we conducted the planned sensitivity analysis of excluding
the findings fromNewton 2005 andVenkatarao 1996, where there
was uncertainty around risk of selection bias and high risk for
attrition bias.
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Infant morbidity
Three studies (Roy 1997; Venkatarao 1996; Vinutha 2000) evalu-
ated and reported infantmorbidity (Analysis 1.24 toAnalysis 1.30)
very low-quality evidence. Although the methods of the Martins
2010 study indicated that infant morbidity was evaluated, the au-
thors did not report this outcome.
Diarrhoea
None of the three studies that considered diarrhoea or gastroen-
teritis reported any significant differences between the vitamin A
supplementationor control groups (Roy 1997 (diarrhoea episodes,
50 participants, P = 0.59), Venkatarao 1996, (RR 1.02, 95% CI
0.98 to 1.06; 456 participants), Analysis 1.24, and Vinutha 2000
(RR 6.03, 95% CI 0.03 to 121.82; 84 participants; very low-qual-
ity evidence), Analysis 1.26.
Respiratory illnesses
The reduced mean duration of acute respiratory tract infection
(3.1 versus 3.7, 50 participants, P < 0.03) in the treatment group
reported by Roy 1997 was not noted in the larger study by
Venkatarao 1996, which reported no evidence of a difference in
overall incidence of one or more episodes to 12 months of age
of acute respiratory infection (RR 1.00, 95% CI 0.96 to 1.03;
456 participants), Analysis 1.27, between the supplemented and
placebo groups. There was also no evidence of a difference in in-
fant upper respiratory infection to three months (RR 0.91, 95%
CI 0.22 to 3.81; 84 participants), Analysis 1.28.
Febrile illness
One small study (Roy 1997) reported a lower mean number of
febrile illness episodes (0.1 versus 0.3, 50 participants, P < 0.002)
in the vitamin A group compared to the control group, Analysis
1.30.
Adverse effects of vitamin A supplementation
No differences were detected in the potential for developing the
adverse effect of bulging fontanelle following vitamin A supple-
mentation (400,000 IU) (RR 2.00, 95% CI 0.61 to 6.55; 444
participants; 1 RCT; low-quality evidence) Analysis 1.31.
Secondary infant outcomes
Infant serum retinol
Four studies reported infant serum retinol between three to three
and a half, and six to six and a halfmonths. There was no beneficial
effect observed in two of the dosing regimens (200,000 to 400,000
IU, or 200,000 IU) used at three to three and half months (MD
0.11 µmol/L, 95% CI -0.05 to 0.26; 379 participants; 4 RCTs;
Tau² = 0.02, I² = 87%; MD 0.20 µmol/L, 95% CI 0.00 to 0.39;
215 participants; 3 RCTs; Tau² = 0.01, I² = 47%), Analysis 1.32,
and there was evidence of substantial heterogeneity. Similarly, no
beneficial effect was observed with the use of 400,000 IU dose
versus placebo at three to three and half months, (MD of 0.02
µmol/L, 95% CI -0.03 to 0.07, 164 participants) (Ayah 2007).
There were no differences at six to six and a half months in any
of the four studies that reported this outcome (Analysis 1.33), for
example, the subgroup analysis of 200,000 to 300,000 IU versus
placebo yielded a MD 0.03 µmol/L (95% CI -0.02 to 0.09; 289
participants; 3 RCTs), although again there was evidence of sub-
stantial heterogeneity. After sensitive analysis, it was observed that
the source of heterogeneity was the Vinutha 2000 study that used
a water-miscible vitamin A formulation, which probably explains
the highest enhancement in serum concentration (MD0.29 µmol/
L) compared to the others studies (MD varying from 0.02 to 0.05
µmol/L).
There was no evidence of a subgroup difference by dose as indi-
cated by the subgroup interaction test.
Vitamin A hepatic reserves
Three studies reported low hepatic vitamin A reserves (Analysis
1.34), but vitamin A hepatic reserves analysed at six to six and half
months of infancy were not enhanced by any vitamin A dosing
regimens, compared with placebo. Substantial heterogeneity was
found in these analyses. As the data from studies that administrated
different doses of vitamin Awere pooled, we used a random-effects
model because its not possible to assume that the results would be
similar among the trials.
There was no evidence of a subgroup difference by dose as indi-
cated by the subgroup interaction test.
Clinical vitamin A deficiency (VAD)
No study addressed infant clinical VAD.
Comparison 2: Supplement (vitamin A as retinyl)
400,000 IU versus 200,000 IU
Primary maternal outcomes
Maternal mortality
No study addressed maternal mortality.
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Maternal morbidity
No study addressed maternal morbidity.
Adverse effects of vitamin A supplementation
Fernandes 2012 noted that the women did not report any adverse
effects related to the double (400,000 IU) or single (200,000 IU)
doses of vitamin A supplementation, however, no data about this
were presented in the publication.
Secondary maternal outcomes
Maternal serum retinol
Two studies presented maternal serum retinol values, assessed be-
tween two and sixmonths postpartum, as described in the Analysis
2.1. There was no evidence that a higher dose of maternal vitamin
A supplementation (400,000 IU) made any difference to serum
retinol concentrations at two months (MD 0.04 µmol/L, 95% CI
-0.06 to 0.14; 429 participants; 2 RCTs; test for subgroup differ-
ences: Chi² = 3.37, df = 2 (P = 0.19), I² = 40.7%) compared to
the standard dose (200,000 IU). The means were not different at
four, and six months postpartum (1 RCT, Fernandes 2012).
Vitamin A hepatic reserves
No study addressed maternal vitamin A hepatic reserves.
Breast milk retinol concentration
Breast milk retinol concentrations were reported by three studies,
but it was only possible to pool the data from two of them (Analysis
2.2). A double dose of vitamin A supplementation (400,000 IU)
was not associated with an increased breast milk retinol concen-
tration at two months (MD -0.01 µmol/L, 95% CI -0.14 to 0.11;
377 participants; 2 RCTs), and at four months (MD -0.03 µmol/
L, 95% CI -0.13 to 0.08; 348 participants; 2 RCTs) postpartum,
(test for subgroup differences: Chi² = 1.07, df = 3 (P = 0.78),
I² = 0%). No difference in breast milk retinol concentration was
observed in the trial by Idindili 2007 (780 women randomised)
at six months (higher dose: mean = 1.82 µmol/L (standard devia-
tion (SD) = 1.09); lower dose: mean = 1.88 µmol/L (SD = 1.09);
P = 0.49) or at nine months postpartum (higher dose: mean =
1.86 µmol/L (SD = 1.19); lower dose: mean = 1.95 µmol/L (SD
= 0.97); P = 0.33).
Regarding the proportion of women with low breast milk retinol
concentrations, only Darboe 2007 assessed this outcome, and no
significant effect was observed (Analysis 2.3).
Clinical and subclinical vitamin A deficiency (VAD)
No study addressed maternal clinical and subclinical VAD out-
comes.
Primary infant outcomes
Infant mortality
No study addressed infant mortality.
Infant morbidity
Only one study (Fernandes 2012) assessed the impact of the ma-
ternal double dose of vitamin A supplementation on infant mor-
bidity. The rates and RR and CIs were reported for the following
infant morbidities (diarrhoea, respiratory illnesses, febrile illness),
but the data were not presented in a way that could be used for
pooled analysis.
Diarrhoea
No differences were observed for diarrhoea episode rates per 100
children per month (400,000 IU: number of episodes = 98, rate =
13.8; 200,000 IU: number of episodes = 89, rate = 13.3; RR 0.96,
95%CI 0.72 to 1.28, P = 0.80) during the sixmonths postpartum.
Respiratory illnesses
The effects of the double dose was evaluated on acute respiratory
infection in episode rates per 100 children per month (Fernandes
2012) until six months postpartum, however no differences were
described (400,000 IU: number of episodes = 319, rate = 44.8;
200,000 IU: number of episodes = 310, rate = 46.2; RR 1.03,
95% CI 0.88 to 1.21, P = 0.70).
Febrile illness
For fever episode rates per 100 children per month, no beneficial
impact was noted with the maternal double or single doses of
vitamin A supplementation (400,000 IU: number of episodes =
185, rate = 26.0; 200,000 IU: number of episodes = 161, rate =
24.0; RR 0.92, 95% CI 0.75 to 1.14, P = 0.46) (Fernandes 2012)
during the six months postpartum.
Adverse effects of vitamin A supplementation
In the trial by Darboe 2007, the field workers questioned the
women about infant adverse effects (fever, nausea, and bulging
fontanelle) at one day before supplementation and on the follow-
ing three days after supplementation, but no reactions were noted.
Fernandes 2012 did not report any infant adverse effects after the
double (400,000 IU) or single (200,000 IU) doses.
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Secondary infant outcomes
Infant serum retinol
Two studies, Darboe 2007 and Fernandes 2012 (Analysis 2.4),
assessed the effects of maternal double (400,000 IU) or single
(200,000 IU) doses of vitaminA supplementation on infant serum
retinol concentrations at two months postpartum; no significant
difference between the regimens was noted (MD 0.01 µmol/L,
95%CI -0.05 to 0.07; 362 participants; 2 RCTs; test for subgroup
differences: Chi² = 0.70, df = 2 (P = 0.71), I² = 0%). For the
following endpoints, four and six months, the absence of effects
was maintained.
Vitamin A hepatic reserve
No study addressed infant vitamin A hepatic reserves.
Clinical vitamin A deficiency (VAD)
No signs of xerophthalmia were observed in the trial by Fernandes
2012.
There was no evidence of a subgroup difference by dose as indi-
cated by the subgroup interaction tests for any of the comparisons
(Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4). Fixed-ef-
fect models were used in these analysis.
D I S C U S S I O N
There was no evidence that different doses of vitamin A supple-
mentation for postpartum women could improve maternal and
infant mortality and morbidity, compared with other doses, no
treatment or placebo. Although maternal serum and breast milk
retinol concentrations improved with supplementation, this did
not translate to health benefits for either women or infants.
The possible explanations for the absence of a definitive finding
are as follows: the limited power of some study samples to detect
an effect on mortality and morbidity; the differing maternal mor-
tality rate (MMR) and infant mortality ratio (IMR) at different
time points when each trial was developed; the overall positive
shift in the MMR and IMR over the decades; the absence of vita-
min A deficiency (VAD) or different degrees of severity amongst
countries, affected by long-term under nutrition that a single or
short course of vitamin A supplementation was unable to redress,
as well as, the overall positive shift over the years; the heterogene-
ity of vitamin A regimens assessed amongst trials; the coexistence
of other micronutrient deficiencies, and their interactions; low-
quality control of vitamin A content capsules; and the limitations
of the biochemical indicators.
Summary of main results
Supplement (vitamin A as retinyl, water-miscible or
beta-carotene) 200,000 to 400,000 IU versus control
(placebo, no treatment, other)
Primary maternal outcomes
Maternal mortality was not influenced by single high-dose vi-
tamin A supplementation (400,000 IU) in two studies, Ayah
2007 and ZVITAMBO Study Group, conducted between 1999
to 2001, and 1997 to 2001, respectively, in areas of high MMR.
In contrast to our findings, one large study carried out in Nepal,
between 1994 and 1997, that evaluated weekly long-term low-
dose supplementation with vitamin A or beta carotene (23,300
IU) for women during pregnancy and the postpartum period
demonstrated a protective effect of vitamin A for maternal mor-
tality (NNIPS-2). However, other subsequent large studies that
assessed similar vitamin A supplementation doses in Bangladesh
(JivitA-1 Trial), carried out between 2001 to 2007, and Ghana
(ObaapaVitA), between 2000 to 2008, have not been able to repli-
cate this effect.
In the trial by Ayah 2007, 564 women were enrolled, compared
with the larger sample in the ZVITAMBOStudyGroup, for which
14,110 women were randomised, but only data regarding 8577
HIV-negative women with vital status were known, and were in-
cluded in the present systematic review. Even so, these sample sizes
are considerably smaller when compared with the 207,781 women
of reproductive age enrolled in theObaapaVitA study. In this trial,
the authors estimated that 82,000 pregnancies would be necessary
to detect a 33% reduction in the associated mortality in the inter-
vention arm. However, as the investigators noted, not even in this
large sample size study could vitamin A prevent maternal mortal-
ity. The differences in MRR by the time each trial was conducted
could also have influenced the various study’s potential for effect.
For example, in Zimbabwe, the MRR was 590 deaths/100,000
live births in 2000, lower than the rate observed in Nepal in 1995
(660) (WHO 2016). Moreover, the overall shifts in MMR over
the years (WHO 2015b; WHO 2015c) could limited the impact.
Several maternal morbidities are more prevalent in populations
known to be vitamin A deficient than in industrialised countries.
However, we did not observe a reduction in maternal morbidity
after postnatal supplementation. Only a protective effect of vita-
min A (300,000 IU) supplementation was observed for the preva-
lence of abnormal conjunctival impression cytology (CIC) from
baseline to six months. This measure of VAD is useful when there
is limited access to laboratory assessment of vitamin A status, but
not an ideal stand-alone indicator of this micronutrient deficiency
(Stoltzfus 1993c). Although the countries in which the studies
were conducted would be considered to be areas of VAD, the re-
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duction of its severity over a number of years could explain the
present results (WHO 2009b).
Secondary maternal outcomes
Maternal supplementation with a single postpartum dose of
200,000 to 300,000 IU vitamin A enhanced thebreast milk
retinol concentration at three to three and a half months postpar-
tum, a more responsive indicator of vitamin A supplementation
than serum retinol concentration (Stoltzfus 1993b). Moreover,
serum retinol has some limitations as an indicator of vitamin A
status, because retinol binding protein is a negative acute phase re-
actant protein (Filteau 1993;WHO1996).Dancheck 2005 inves-
tigated the influence of acute phase reaction in breast milk retinol
concentration in women from Malawi. The authors observed no
significant differences in retinol concentration between lactating
women with or without signs of inflammation. Thus, the meta-
analyses of breast milk retinol in this review are probably more
informative than serum retinol in assessing the impact of vitamin
A supplementation.
There is concern that maternal administration of 400,000 IU in a
single dose may cause a transient rise in breast milk retinoic acids
and toxicity (Ross 2002). For this reason, the International Vita-
min A Consultative Group (Ross 2002) recommends an interval
of at least 24 hours between the two doses (200,000 IU each)
for a total 400,000 IU vitamin A. Despite this recommendation,
the full 400,000 IU was administered as one dose in two stud-
ies (ZVITAMBO Study Group; Ayah 2007), with no reports of
breast milk retinoic acid concentration immediately after supple-
mentation.
No included studies demonstrated differences in the proportion
of those with signs or symptoms likely to be associated with the
potential adverse effects from vitaminA supplementation, such as
abdominal pain, vomiting, poor appetite, headaches, drowsiness,
nausea or blurred vision.
Although serum retinol concentration has some limitations as an
indicator, the Global WHO database on VAD, a part of the Vita-
min and Mineral Nutrition Information System (VMNIS), com-
piles data on the prevalence of clinical VAD (night blindness and
ocular manifestation) and blood retinol concentration regularly
from scientific literature and collaborators to estimate the preva-
lence of VAD around the world. These estimates provide valuable
information formonitoring global progress and for evaluating cur-
rent strategies to reduce VAD (WHO 2009b). The pooled analy-
sis of the reviewed studies showed that maternal supplementation
(200,000 to 300,000 IU) is associated with reduced proportions
of low vitamin A hepatic reserves and significantly higher serum
retinol concentration only until three months postpartum.
Primary infant outcomes
There was no evidence that postpartum maternal vitamin A sup-
plementation influenced infant mortality in the five studies that
each measured this outcome at different times (between two and
12months) (Ayah 2007;Martins 2010;Newton2005;Venkatarao
1996; ZVITAMBO StudyGroup). Only one small study included
in the present review observed an impact on infant morbidity
(duration of acute respiratory illness, number of febrile illnesses)
(Roy 1997). Our results corroborate with the body of evidence
presented in the systematic review by Gogia 2011, which observed
no association between maternal and/or infant vitamin A supple-
mentation on infant morbidity and mortality up to 12 months
postpartum.
The coexistence of multiple micronutrient deficiencies could also
be a factor that influenced the results. In a systematic review by
Haider 2015 that assessed the effects of multiple-micronutrient
supplementation for pregnant women, a significant decrease in the
low birthweight, small-for-gestational age, and stillbirth rate was
observed. Nonetheless, no beneficial impact on maternal, perina-
tal, or neonatal mortality was noted. Thus, further studies that
consider fetal/neonatal/infant outcomes, as morbidities, following
maternal multiple-micronutrient supplementation during preg-
nancy, breastfeeding, or both, may therefore be of interest.
Concern has been expressed about adverse effects from infant
supplementation with high doses of vitamin A (more than 50,000
IU; Allen 2002), however studies included in this review did not
report increased adverse signs and symptoms among infants after
high-dose postpartum maternal supplementation.
Secondary infant outcomes
Regarding theinfant serum retinol and hepatic vitamin A re-
serves,noprotective effect ofmaternal vitaminA supplementation
(200,000 to 400,000 IU) was observed (Ayah 2007, RETIBETA
Project; Stoltzfus 1993a; WHO/CHD IVASSG).
A case-control study by Rondó 1997 conducted with Brazilian
infants observed that cord blood retinol concentration was higher
in infants with adequate growth for gestational age at the time of
birth compared with infants with intrauterine growth restriction.
According to the authors, one possible explanation for this result is
maternal VAD. In our review, we included one study (Ayah 2007)
that investigated the interaction of birthweight in the response to
the vitaminA supplementation, but the authors found no evidence
of effect. The studies included in this present systematic review
did not provide data in a format that would allow us to perform
subgroup analysis considering birthweight, although future studies
may consider this.
The absence of effect can also be influenced by the low-quality
control of the supplements.Only one studymonitored the vitamin
A content in the capsules during the trial and demonstrated that
the vitamin content was stable in the capsules administered to the
women. However, the lower-dose capsules administered to infants
(results not included in this review) were subject to deterioration
over time by up to 32% of expected content (Idindili 2007). Thus,
the stability of vitamin A capsules should be considered in further
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studies and routine supplementation programmes (Idindili 2007;
Newton 2008).
Supplement (vitamin A as retinyl) 400,000 IU versus
200,000 IU
A total of three studies (Darboe 2007; Fernandes 2012; Idindili
2007) evaluated the effects of two high doses of 200,000 IU vi-
tamin A (400,000 IU) versus one dose (200,000 IU) and no im-
provements in maternal and infant health were observed. In these
studies, women were supplemented with two doses of 200,000
IU with an interval of 24 hours, eight to 10 days, or one month,
respectively, and no data regarding breast milk retinoic acid con-
centration were reported.
Overall completeness and applicability of
evidence
We are confident that the search strategy was conducted in a ro-
bust and structured format to ensure capture of relevant studies
for this review. The evidence was generated from studies that were
conducted in areas of VAD (WHO 2009b). Even so, in most of
the studies the baseline mean maternal serum concentrations were
above the cut-off point proposed by WHO (WHO 1996). De-
spite this, our findings may be interpreted to represent chronic
inadequate vitamin A reserves for women’s health needs in these
populations, which translated to infants born with inadequate re-
serves. This sub-optimal ’starting point’ could not be corrected by
postpartum administration of vitamin A to women, specifically
when breastfeeding. Other systematic reviews of long-term sup-
plementation to women during their reproductive years (includ-
ing the postpartum period) and of infant supplementation may
examine whether long-term preventive supplementation confers
greater benefits thanpostpartum supplementation, that is, after the
time when the infant has already received inadequate provision of
vitamin A during pregnancy (Haider 2015; McCauley 2015). As
noted by Sommer 2012, the limited evidence to date on the value
of vitamin A supplementation needs to be further explored before
widespread implementation of carotenoid supplementation.
Quality of the evidence
We judged the included trials to provide moderate- and low-qual-
ity evidence for the lack of differences in maternal and infant mor-
tality, respectively; very low-quality evidence for maternal or in-
fant morbidity; low-quality evidence for the lack of adverse effects
of supplementation; and low-quality evidence that supplementa-
tion improved breast milk retinol levels (See: Summary of findings
for the main comparison). The quality ratings were influenced
by a number of factors, including the risk of bias: inadequate re-
porting of randomisation and allocation concealment or reasons
for attrition. The studies were considered overall as being at low
or unclear risk of bias, although some ratings of high risk were
considered, for example where the control group was unblinded.
Many of the studies enrolled small numbers, with few events, with
wide 95% confidence intervals crossing the line of no effect and so
were downgraded for imprecision. There was also some evidence
of inconsistency as indicated by high statistical heterogeneity. In
addition, some studies were sponsored by industry (or did not
report funding) and undertook measures of mortality, morbidity
and biological assays at a wide range of time points, limiting the
potential for meta-analysis. However, we also judged that any bias
was unlikely to have obscured a true effect of vitamin A (should it
have existed).
Potential biases in the review process
We used several approaches in an attempt to minimise bias. The
search strategy incorporated both the trials register of theCochrane
Pregnancy and Childbirth Group and other databases that were
likely to include publications from less well-developed countries
that may not be identified through standard searches. The review
authors independently assessed eligibility for inclusion, conducted
data extraction and negotiated on areas of concern or uncertainty.
Considering the high number of meta-analyses, there is a risk of
spuriously significant results.
Agreements and disagreements with other
studies or reviews
Although the studies included in this review did not report in-
creased adverse signs and symptoms among infants after high-dose
postpartum maternal supplementation, the systematic review by
Gogia 2011, reported that meta-analysis of two studies demon-
strated an increase in the risk of bulging fontanelle after a second
or third dose of vitamin A given directly to the infant. In view
of this, future studies of maternal supplementation still need to
consider the potential for this adverse effect that may be associated
with cumulative or high doses of supplements.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In countries with widespread breastfeeding practices and high
prevalences of vitamin A deficiency (VAD), the transient improve-
ment in maternal serum retinol concentration and breast milk
retinol represent at least a limited benefit of vitamin A supple-
mentation for postpartum women. These findings need to be con-
sidered in the context of the potential for follow-up with longer-
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term supplementation to ultimately improve maternal and infant
health outcomes.
No vitamin A supplementation regimens report adverse effects for
women or their infants, in regions of VAD.
This review has not evaluated vitamin A supplementation in non-
deficient populations.
Implications for research
This review’s focus on postpartum supplementation needs to be
considered as part of a wider focus on vitamin A status during
infancy and for women, across their reproductive years, including
the ideal dosing regimen to achieve improved maternal and infant
health for those residing in countries of VAD, where there are also
high rates of maternal and infant mortality. Moreover, the stability
of vitamin A content in capsules needs consideration.
Further research may consider the potential interaction between
vitamin A and other micronutrients, including iron and zinc.
Other sustainable long-term strategies to achieve food and nu-
trition security, as increased access to local vitamin A rich foods,
through agriculture- and nutrition-based interventions, and food
and nutrition education, are also warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ayah 2007
Methods Randomised, double-blind, placebo-controlled, 2 by 2 factorial trial
Participants Women giving birth to a live single baby and their infants.
Bondo, Kenya.
N = 564 women and their infants.
Interventions Single dosage administered to women within 24 hours of birth; single dosage to infant
at 1-4 weeks of age
All infants received 100,000 IU vitamin A at 8 months of age (after trial)
4 intervention groups:
1. Women received 400,000 IU vitamin A and infant received 100,000 IU vitamin A as
retinyl palmitate (n = 142).
2. Women received 400,000 IU vitamin A and infant received placebo (n = 140).
3. Women received placebo and infant received 100,000 IU vitamin A (n = 143).
4. Women received placebo and infant received placebo (n = 139)
Outcomes Maternal serum and breast milk retinol concentrations. Infant serum retinol concentra-
tion and vitamin A hepatic stores (MRDR)
Notes No information regarding breastfeeding pattern was provided. However, at least some
breastfeeding is implied by the analysis of breast milk retinol at 6 months for 63% of
the women originally enrolled
87.4% of follow-up until 14 weeks, 77.1% of follow-up until 26 weeks postpartum
The prevalence of HIV infection among antenatal attendees was above 28% at the time
of the study. However, the trial was conducted prior to availability of HIV testing and
anti-retrovirals for antenatal women in western Kenya. Thus, it was not possible to know
the prevalence of HIV among recruited women
Sample size calculation reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Two random sequences of X and Y were
prepared, one for the mothers and one for
the infants. Identification numbers from
1 to 700 were assigned consecutively to
each of the two lists and mother-infant
pairs of capsules were packaged in zip-lock
bags numbered from 1 to 700 and kept in
batches of ten.”
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Ayah 2007 (Continued)
Allocation concealment (selection bias) Low risk “The randomisation codes were concealed
for the entire trial duration and only re-
vealed after completion of data analysis.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “...prepared and supplied the vitamin A
and identical-looking placebo supplements
as oily capsules in brown bottles coded as
X or Y.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The randomisation codes were concealed
for the entire trial duration and only re-
vealed after completion of data analysis.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All analyses were by ITT.
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes re-
ported.
Other bias High risk Supported by Hoffmann-La Roche Ltd
(Basel Switzerland).
Bhaskaram 2000
Methods Randomised, double-blind, placebo-controlled trial.
Participants Hospital-based study with postpartum women who did not receive any vitamin A sup-
plements during pregnancy and had uncomplicated full-term births
Hyderabad, India.
N = 102 women and their infants.
Interventions Single high dose to women within 24 hours after birth.
2 intervention groups:
1. Women received 200,000 IU vitamin A as retinyl palmitate (n = 50).
2. Women received placebo (n = 52).
Outcomes Infant serum retinol concentration, corneal lesions and breast milk retinol concentration
Notes All infants given OPV within 72 hours after birth.
All infants breastfed, followed up at 6 months.
100% of follow-up until 6 weeks, 87% followed up until 3 months, 46% followed up
until 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
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Bhaskaram 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, no details provided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Vitamin A and placebo were coded by a
person who had no connection with the in-
vestigation and the dose was administered
by an auxiliary nurse midwife who was not
aware of the code.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not reported, but outcomes (serum and
breast milk retinol concentration) were un-
likely to be influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. ITT analyses not performed
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes re-
ported.
Other bias Unclear risk Source of funding not mentioned. No
mention of any research protocol published
a priori
Darboe 2007
Methods Randomised, double-blind, placebo-controlled trial.
Participants Postpartum women without severe peripartum difficulties or preterm birth, with new-
borns ≥ 2200 g with no congenital defects at birth
Keneba and West Kiang, Gambia.
N = 220 women and their infants.
Interventions Single or double high dose to women at delivery (first dose) and within a week (second
dose); and 3 high doses to infant at 2, 3 or 4 months
All infants received 100,000 IU vitamin A at 9 months and 200,000 IU at 12 months
postpartum
2 intervention groups:
1. Women received 400,000 IU vitamin A as retinyl palmitate and infant received 150,
000 IU vitamin A (3 doses of 50,000 IU) (n = 110).
2. Women received 200,000 IU and infant received placebo (3 doses) (n = 110)
Outcomes Maternal morbidity, serum and breast milk retinol concentrations. Infant morbidity,
haemoglobin and serum retinol concentrations
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Darboe 2007 (Continued)
Notes No information regarding breastfeeding pattern was provided. However, at least partial
breastfeeding is implied by the reported analysis of breast milk retinol to 6 months in
88% of those enrolled
89.5% of follow-up until 12 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent senior scientist packed
and labelled the supplements, and did a
block randomisation procedure (16 per
block) to allow for possible effects of season
of
birth.”
Allocation concealment (selection bias) Low risk “All members of the trial team were un-
aware of allocation until the data had been
cleaned and locked.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Vitamin A in vegetable oil and vegetable
oil placebo were prepared by Hoffmann La
Roche (Basel, Switzerland). An indepen-
dent senior scientist packed and labelled
the supplements, and did a block randomi-
sation procedure (16 per block) to allow
for possible effects of season of birth. Sup-
plements or placebo were directly admin-
istered at home by field staff , apart from
supplements at 2, 9, and 12 months, which
were given at the clinic during follow-up.
All members of the trial team were un-
aware of allocation until the data had been
cleaned and locked.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All members of the trial team were un-
aware of allocation until the data had been
cleaned and locked.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition and exclusions were
reported in detail, although ITT analysis
was not performed
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes re-
ported.
Other bias Low risk Trial registered a priori (No. ISRCTN
98554309). The UK Medical Research
Council funded the study, and laboratory
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Darboe 2007 (Continued)
analyses in Coleraine were supported by
BASF Aktiengesellschaft (Ludwigshafen,
Germany)
Fernandes 2012
Methods Randomised, triple-blind, placebo-controlled trial.
Participants Women with 13 to 42 years of age, low obstetric risk, no gemelar and at-term gestation
and their infants
Recife, Permambuco, Brazil.
N = 312 pairs of women and infants.
Interventions Single or double high dose to women at delivery (first dose) and within 8-10 days (second
dose)
2 intervention groups:
1. Women received 200,000 IU immediately postpartum + 200,000 IU vitamin A as
retinyl palmitate at 8-10 postpartum (n = 152).
2. Mother received 200,000 IU vitamin A as retinyl palmitate immediately postpartum
+ placebo as soy oil capsules at 8-10 postpartum (n = 160)
(All capsules had 40 mg vitamin E.)
Outcomes Infant sides effects (vitamin A toxicity); duration and severity of episode of diarrhoea,
fever, acute respiratory infection, otitis, VAD (signs of xerophthalmia), hospitalisations,
severity signs (venous rehydration, antibiotic therapy) and serum retinol concentration.
Maternal side effects (vitamin A toxicity), serum and breast milk retinol concentrations
Notes At least 60.45% of follow-up until 6 months.
At least 70.6% of breastfeeding until 6 months.
Registered at Clinical Trials: NCT00742937.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Mother-child pairswere assigned, through
a simple randomization process by using
a random number table into 2 treatment
groups.”
“[…] using a random number table gener-
ated by EPI INFO […]”
Allocation concealment (selection bias) Low risk “The randomization codes were kept secret
during the whole study...”; “The placebo
capsules had the same consistency, vehicle,
coloration and flavour as the vitaminA cap-
sules.”; “The research members were only
informed of the allocation of the supple-
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Fernandes 2012 (Continued)
mentation groups after the completion of
data analysis.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical capsules were used in the trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was kept until end of the trial.
Incomplete outcome data (attrition bias)
All outcomes
High risk ”However, those who did not breastfeed
their infants were not excluded from the
study and received the normal follow-up
for illness in their infants (i.e. follow-upwas
on an intention-to-treat basis).”
“The nursing mothers who were not exclu-
sively breastfeedingwere not excluded from
the research, and were still followed up and
assessed based on the study design, that is,
in terms of “intention to treat”.”
The authors probably performed an avail-
able-case ITT. It is possible to notice an im-
balanced loss of follow-up comparing the
arms. In the publication about breast milk;
only 4-month data are reported
Selective reporting (reporting bias) High risk Fetal growth as outcome in trial registra-
tion, only baseline data reported
Other bias High risk In the 4 papers the authors reported differ-
ent number of randomisation and baseline
characteristics
Idindili 2007
Methods Randomised, double-blind, placebo-controlled trial.
Participants Women resident in the study area that brought their infants for vaccination
Ifakara, Tanzania.
N = 780 women and their infants.
Interventions Single or double high dose to women within 1 week after delivery; and 3 standard or
higher doses to infant at 1, 2 or 3 months (DPT/OPV vaccination)
All infants received 100,000 IU vitamin A at measles vaccination (9 months)
2 intervention groups:
1. Women received 200,000 IU vitamin A as retinyl palmitate and infant received 75
000 IU vitamin A (3 doses of 25 000 IU) (n = 390).
2. Women received 400,000 IU vitamin A and infant received 150,000 IU vitamin A
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Idindili 2007 (Continued)
(3 doses of 50,000 IU) (n = 390)
Outcomes Infant morbidity, anaemia (packed cell volume), serum retinol concentration, vitamin
A hepatic stores (MRDR) and breast milk retinol concentration
Notes At least 86% of infants were exclusively breastfed until 1 month
81% of follow-up until 3 months; 79.5% until 6 months; and 77.2% until 9 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Individual randomizationwas achieved by
using a list of study numbers that had been
randomly assigned to an intervention arm
in blocks of 10, generated by the Data and
Safety Monitoring Board.”
Allocation concealment (selection bias) Low risk “A compact disk containing the cleaned
and locked database files was exchanged for
the treatment randomization code, held by
the Data and Safety Monitoring Board.”
All members of the trial team were un-
aware of allocation until the data had been
cleaned and locked
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Vitamin A capsules providing different
doses were manufactured by Accucaps In-
dustries (Windsor, Canada) (25,000 and
50,000 IU) and RpScherer (Aprilia, Italy)
(200,000 IU), and were supplied to the
project by the WHO.”
Not enough detail to judge whether partic-
ipants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details were given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. ITT analyses not performed
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes re-
ported.
Other bias Unclear risk Post hoc analyses were conducted because
of concerns that the capsules did not con-
tain the necessary amount of vitamin A (in
a sample of capsules vitamin degraded)
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Idindili 2007 (Continued)
Supported by Immunization Vaccines &
Biologicals (the World Health Organi-
zation and the United Nations Foun-
dation), Sight&Life (Hoffman-la Roche
Ltd), Micronutrient Initiative, the Cana-
dian International Development Agency,
and the United Nations Children’s Fund
(UNICEF)
Martins 2010
Methods Randomised, double-blind, placebo-controlled trial.
Participants Women and their infants from a community attended at a Basic Health Unit
Ribeirão Preto, São Paulo, Brazil.
N = 66 women and their infants.
Interventions Single high dose to women between the 20 and 30th days postpartum compared with
placebo
2 intervention groups:
1. Women received 200,000 IU (retinyl palmitate) between the 20 and 30th days post-
partum (n = 33).
2.Women received a placebo as soy oil capsules between the 20 and 30th days postpartum
(n = 33)
Outcomes Infant febrile and/or diarrhoeic episode during the preceding 15 days (collected from
the medical records) and at 3 months of life and serum retinol concentration. Maternal
serum and breast milk retinol concentrations
Notes 89.39% of follow-up until 3 months.
75.4% of exclusive breastfeeding until 3 months.
No trial register.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No explicit randomisation procedure re-
ported.
“[…] assigned at random […]”.
Allocation concealment (selection bias) Unclear risk Not mentioned at all.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind trial” “who received identical
capsules containing soy oil […]”
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Martins 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “double-blind trial”, not specified, but re-
ported outcomes unlikely to be influenced
by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Data analysis was based on intent to treat
because the mothers who interrupted ex-
clusive breast-feeding were not excluded.”
Similar missing data in both groups,
dropout explained, available case ITT per-
formed
Selective reporting (reporting bias) High risk CRP levels only reported as baseline level.
Febrile or diarrhoeic episodes not reported
Other bias Low risk No other source of bias could be detected.
Newton 2005
Methods Randomised, double-blind, placebo-controlled 2 x 2 factorial design trial
Participants Women 3-4 weeks postpartum and their infants.
Kintampo, Brong Ahafo Region, Ghana.
N = 1085 women and their infants.
Interventions 4 intervention groups:
1. Women received 200,000 IU of vitamin A as retinyl palmitate at 3-4 weeks and infant
received total of 75,000 IU (25 000 IU at 6, 10 and 14 weeks) (n = 274)
2. Women received placebo at 3-4 weeks and infant received total of 75 000 IU (25,000
IU at 6, 10 and 14 weeks) (n = 265)
3. Women received 200,000 IU of vitamin A as retinyl palmitate and infant received
total of placebo (n = 269)
4. Women received placebo and infant received placebo at 6, 10 and 14 weeks (n = 277)
Outcomes Infant mortality, infant serum antibody titres for polio and tetanus at 6 months of age
Notes No information supplied regarding breastfeeding rates. The report’s background out-
lined the evaluation of whether maternal supplementation alone could achieve adequate
vitamin A status, without the need for infant supplementation. This suggests that women
were breastfeeding
Infant supplementation linked to time of administration of diphtheria pertussis tetanus
and polio vaccinations
It was confirmed with the first author that the mortality data in the study referred to
infants
Risk of bias
Bias Authors’ judgement Support for judgement
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Newton 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Mothers and infants were allocated to 1
of 4 treatment groups, using a blocked ran-
domization scheme.”
Allocation concealment (selection bias) Unclear risk Details not provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The test and placebo capsules were iden-
tical in size colour and shape.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but outcomes were unlikely
to be influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Only infants of women for which blood
sample was obtained in the end of the study
were included in the analysis. Attrition was
34.6%
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes were
reported.
Other bias Unclear risk Enrolment of participants was extended to
higher thanplanned lost to follow-up. Sam-
ple size calculation provided, but unclear
whether a protocol was published a priori.
Supported by a grant from the Wellcome
Trust
RETIBETA Project
Methods Randomised, double-blind, placebo-controlled trial.
Participants Community-based study with women at 1-3 weeks after birth.
Matlab, Bangladesh.
N = 220 women and their infants.
Interventions Single high dose to women within 1-3 weeks postpartum or beta-carotene daily for 9
months
3 intervention groups:
1. Women received 200,000 IU of vitamin A as retinyl palmitate and placebo daily for
9 months postpartum (n = 74).
2.Women received placebo and 7.8 mg (1 300 µg RE or 4327 IU) of beta-carotene daily
until 9 months postpartum (n = 73).
3. Women received placebo and placebo daily until 9 months postpartum (n = 73)
Outcomes Maternl vitaminAhepatic stores (MRDR), serumand breastmilk retinol concentrations.
Infant serum retinol concentrations and vitamin A hepatic stores (MRDR), Both in a
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RETIBETA Project (Continued)
subsample of women and infants
Notes All Infants at least partially breastfed to 6 months of age.
87% ate complementary food during this period.
98% follow-up rates until 3 months, 95% until 6 months, and 92% until 9 months
postpartum
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Before beginning the study, individual
treatment codes and follow-up schedules
were assigned to a sequence of identifi-
cation numbers in blocks of 18 using a
random number table”...“Each block con-
tained all possible combinations of three
treatment groups.”
Allocation concealment (selection bias) Low risk “The study capsules were manufactured by
Tischon Corporation (Salisbury, MD) and
delivered to the field and to study partici-
pants coded as type A, B or C.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules: packaged in blister pack strips.
Vitamin A and placebo capsules differed
in colour slightly - authors considered that
foil packagingwould reduce direct compar-
isons between groups. Beta-carotene and
placebo capsules identical in colour
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but outcomes were unlikely
to be influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. ITT analyses not performed
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes were
reported.
Other bias Unclear risk Supported by cooperative agreements be-
tween The Johns Hopkins University
School of Hygiene and Public Health, Bal-
timore,MD, USA and theOffice of Health
and Nutrition, U.S. Agency for Inter-
national Development, Washington, DC
(DAN-5116-1-00-8051-00 and HRN-A-
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RETIBETA Project (Continued)
00-97-00015-00). Research protocol not
published a priori
Roy 1997
Methods Randomised controlled trial.
Participants Postpartum women.
Dhaka, Bangladesh.
N = 50 women and their infants.
Interventions Single high dose to women within 24 hours after birth.
2 intervention groups:
1. Women received 200,000 IU vitamin A as retinyl palmitate plus 60 mg of iron daily
for 9 months (n = 25).
2. Women received 60 mg of iron daily for 9 months (n = 25).
Outcomes Maternal serum and breast milk retinol concentrations. Infant morbidity
Notes All babies were breastfed until 6 months postpartum.
No information regarding breastfeeding pattern was provided.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Women were randomly allocated to either the interven-
tion or control group. No further details provided
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Women in the control group did not receive a placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Field workers who assessed the outcomes were not aware
of the objective of the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were accounted for in the
analysis
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes were reported.
Other bias Unclear risk Study supported by the International Centre for Diar-
rhoeal Disease Research and the United States Agency
for International Development. Research protocol not
published a priori
43Vitamin A supplementation for postpartum women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stoltzfus 1993a
Methods Randomised, double-blind, placebo-controlled trial.
Participants Women at 1-3 weeks postpartum.
Java, Indonesia.
N = 153 women and their infants.
Interventions Single high dose to women within 1-3 weeks after birth.
2 intervention groups:
1. Women received 300,000 IU vitamin A as retinyl palmitate (n = 77)
2. Women received placebo (n = 76).
Outcomes Maternal abnormal CIC, serum and breast milk retinol concentrations. Infant serum
retinol concentration and vitamin A hepatic stores (RDR)
Notes No specific information regarding breastfeeding pattern was provided. However, the
report’s title, background and analysis of breast milk retinol to 8 months postpartum
strongly suggest that infants received at least some breast milk for the duration of the
study. Additionally, it is noted that the 3 women who stopped breastfeeding were not
included in the 6-month follow-up
88.9% follow-up rate until 6 months postpartum.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Individual randomization to treatment
codes A and B was done in blocks of eight
according to the Moses-Oakford assign-
ment algorithm.”
Allocation concealment (selection bias) Low risk “The allocation of treatment codes A and B
to vitamin A or placebo capsules was done
by the Sight and Life Task Force, Hoff-
mann-LaRoche (Basel, Switzerland), who
prepared the capsules.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Vitamin A and placebo capsules “looked
practically identical” and were prepared by
“Sight and Life Task Force, Hoffmann-
LaRoche” - in labelled foil packs
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All investigators, field and laboratory staff
and study participants were blinded to the
randomization code until field work was
completed.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for attrition and exclusions not re-
ported. ITT analyses not performed
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Stoltzfus 1993a (Continued)
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes were
reported.
Other bias Unclear risk Supported by a grant from theThrasherRe-
search Fund and a National Science Foun-
dation Graduate Fellowship to Rebecca I.
Stoltzfus. Study protocol not published a
priori
Venkatarao 1996
Methods Randomised, double-blind, placebo-controlled trial.
Participants Women at 1-2 weeks after birth.
Tamil Nadu, India.
N = 909 women and their infants.
Interventions Single high dose to women within 1-2 weeks after birth and high dose to infant at 6
months
3 intervention groups:
1. Women received 300,000 IU vitamin A as retinyl palmitate and Infant received 200,
000 IU vitamin A (n = 301)
2. Women received 300,000 IU vitamin A and Infant received placebo (n = 297)
3. Women received placebo and Infant received placebo at 6 months of age (n = 311)
Outcomes Infant morbidity and adverse effects.
Notes 99.7% of infants were breastfed for at least 6 months. No information regarding breast-
feeding pattern was provided
75.8% follow-up rate until 12 months postpartum.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomly allocated”. No further details
given.
Allocation concealment (selection bias) Unclear risk “ theMedicalOfficer...administered the ap-
propriate capsules to the mother from the
sealed envelope supplied by the Statistical
Section at the Camp Office.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules were “similar in colour”. Infant
syrup matched for colour and consistency
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Venkatarao 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors did not know about the
intervention.
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusions and attrition were 23%. ITT
analyses not performed
Selective reporting (reporting bias) High risk Not all expected outcomes reported.
Other bias Unclear risk Source of funding not provided. No men-
tion of research protocol
Vinutha 2000
Methods Randomised, controlled trial.
Participants Postpartum women (primigravid and second-gravid).
Mumbai, India.
N = 109 women and their infants.
Interventions Single high dose to women within 48 hours after delivery.
2 intervention groups:
1. Women received 200,000 IU vitamin A as Aquasol water-miscible (n = 53)
2. Women did not receive vitamin A or placebo (n = 56).
Outcomes Maternal serum and breast milk retinol concentrations. Infant serum retinol concentra-
tion
Notes All babies were exclusively breastfed.
77.1% follow-up rate until 3 months postpartum.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised. No further details provided.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Women in the control group did not receive a placebo.
No other details provided on blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Probably not blinded, but outcomes were unlikely to be
influenced by blinding
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Vinutha 2000 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for attrition and exclusions not reported. ITT
analyses not performed
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes were reported.
Other bias Unclear risk Fundedby the LokmanyaTilakMunicipalMedical Col-
lege and Hospital in Mumbai. Study protocol not pub-
lished a priori
WHO/CHD IVASSG
Methods Randomised, double-blind, placebo-controlled, multicentre trial (India, Ghana, and
Peru)
Participants Postpartum women and their infants.
New Delhi, India; Brong Ahafo, Ghana; Lima, Peru.
N = 7078 women and their infants.
Interventions Single high dose to women within 21-42 days after birth in Ghana and 18-28 days after
birth in Peru and India
3 doses to infant during their DPT or OPV immunization (6, 10, 14 weeks) in Ghana,
India and (2, 3 and 4 months) in Peru
Multicentre trial - at 9 months, infants received 25,000 IU vitamin A with measles
immunisation and infants from the control group received single high dose 100,000 IU
vitamin A
Ghana trial - at 6 months, infants received 25,000 IU vitamin A and infants from the
control group received single high dose 100,000 IU vitamin A
Multicentre trial - 2 intervention groups:
1. Women received 200,000 IU vitamin A as retinyl palmitate and Infants received 100,
000 IU vitamin A (4 doses 25,000 IU) (n = 3522)
2. Women received placebo and Infants received placebo (3 doses) plus 100,000 IU
vitamin A at 9 months (equivalent total dose received by group 1) (n = 3556)
Ghana - 4 intervention groups:
1. Women received 200,000 IU vitamin A as retinyl palmitate and Infants received 100,
000 IU vitamin A (4 doses 25,000 IU) (n = 196).
2. Women received placebo and Infants received vitamin A as per group 1 (n = 192).
3. Women received vitamin A as per group 1 and Infants received placebo at times of
immunisation, plus 100,000 IU vitamin A at 6 months (equivalent total dose received
by groups 1 and 2) (n = 185).
4. Women received placebo and Infants received placebo (3 doses), plus 100,000 IU
vitamin A at 6 months (equivalent total dose received by groups 1 and 2) (n = 194)
Outcomes Maternal serum and breast milk retinol concentrations. Infant mortality, morbidity,
acute toxic effects, serum retinol concentration and vitamin A hepatic stores (MRDR)
Notes At least 99.4% of infants were breastfed at enrolment. The sub-study that reported
breast milk retinol gave these findings for 570 women, compared with 631 at 2 months,
suggesting that the majority of infants were at least partially breastfed to 9 months
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WHO/CHD IVASSG (Continued)
74.9% follow-up rate until 12 months postpartum.
Before and periodically during the study standardisation exercises to assess agreement
within and between observers were conducted for the main outcome variables
Standardisation across sites (Ghana, India and Peru) was ensured by exchange visits
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Identification numbers were generated by
computer at the data management centre
at John Hopkins University in Baltimore,
and assigned as random permuted blocks
of size eight.”
Allocation concealment (selection bias) Low risk “Three sealed copies of study codes were
prepared and kept at WHO in Geneva,
with the ethics committee of the All In-
dia Institute of Medical Sciences in New
Delhi, and at the data management centre
inBaltimore. Accesswas limited to one data
manager, who had no direct involvement in
the data analysis, and who prepared infor-
mation requested by the treatment effects
monitoring committee.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The supplements and placebo, in identi-
cal opaque gelatin capsules, were packaged
in individually coded blister packs in Bal-
timore.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All analyses were by intent to treat from
the time of first administration of study
capsule to the mother.”
Selective reporting (reporting bias) Low risk All expected clinically relevant outcomes
were reported.
Other bias Low risk Trial supported by the Child Health and
DevelopmentDivision ofWHO, the Johns
Hopkins Family Health and Child Survival
Cooperative Agreement (HRN 5986-A-
00-6006-00)with funding from theUnited
States Agency for International Develop-
ment, and the Indian Council of Medical
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WHO/CHD IVASSG (Continued)
Research. A study protocol was not men-
tioned but study described in detail
ZVITAMBO Study Group
Methods Randomised, double-blind, placebo-controlled, 2 by 2 factorial trial
Participants Postpartum women without a life-threatening condition and their infants with birth-
weight ≥ 1500 g from urban maternity centres.
Harare, Zimbabwe.
N = 14,110 women and their infants (n = 9562 HIV-negative women)
Interventions Double high dose to women within 96 hours of birth and single high dose to infant
4 treatment groups:
1. Women received 400,000 IU vitamin A as retinyl palmitate and infant received 50,
000 IU vitamin A (n = 3529)
2. Women received 400,000 IU vitamin A and infant received placebo (n = 3529)
3. Women received placebo and infant received 50,000 IU vitamin A (n = 3530)
4. Women received placebo and infant received placebo (n = 3522)
Outcomes Maternal mortality, morbidity, serum retinol concentration and haemoglobin concen-
tration. Infant mortality, acute adverse effects (for 788 women-infant pairs only) and
serum retinol concentration
Infant cause of death was determined from medical records when the death occurred in
the hospital or from a review of verbal autopsy information by study paediatrician
Notes All women initiated breastfeeding (97% started breastfeeding within 12 hours postpar-
tum). 99.5% were still breastfeeding at 6 months and 85.8% at 12 months postpartum
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A separate team at Johns Hopkins Uni-
versity prepared the study capsule pack-
ets. Study identification numbers were ran-
domly allocated to the treatment groups
by computer in blocks of 12. The num-
bers were printed on adhesive labels and af-
fixed to amber-colored zip-lock plastic bags
that were packed with the assigned cap-
sules. Capsule packets were prepared sep-
arately for each of the 4 treatment groups
and were then merged into numeric order
before shipping to Zimbabwe, where a se-
ries of packets were distributed to each re-
cruitment site. As each mother-infant pair
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ZVITAMBO Study Group (Continued)
was recruited, the capsules in the next se-
quential bag were administered, and the as-
sociated study number was assigned to the
pair.”
Allocation concealment (selection bias) Low risk “Lists linking the study number to the
treatmentwere kept in sealed envelopes and
encrypted computer files.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo and treatment capsules appeared
identical. Preparation, randomisation and
packing of capsules were performed at The
Johns Hopkins University in the USA be-
fore shipping to HaTarea.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded to inter-
vention or control.
Incomplete outcome data (attrition bias)
All outcomes
High risk “Only infants of mothers who remained
HIV-negative to 12 months postpartum
were included in the current analysis.”
Attrition was 11.3% (in both the vitamin
A and placebo groups) for HIV-negative
women (985/9562)
Adverse event data were only available for
a subset of 788 women-infant pairs
The analyses were not by ITT.
Selective reporting (reporting bias) High risk Not all clinically relevant outcomes were
reported.
Other bias Low risk “The ZVITAMBO Project was primarily
supported by the Canadian International
Development Agency (R/C Project 690/
M3688), the US Agency for International
Development (cooperative agreement no.
HRN-A-00-97-00015-00 between Johns
Hopkins University and the Office of
Health and Nutrition of the USAID), and
a grant from the Bill and Melinda Gates
Foundation (Seattle); additional support
was provided by the Rockefeller Founda-
tion (NewYork) and BASF (Ludwigshafen,
Germany).”
CIC: conjunctival impression cytology
CRP: C-reactive protein
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DPT: diphtheria, pertussis, tetanus vaccine
ITT: intention-to-treat
IU: international unit
MRDR: modified relative dose response
OPV: oral polio vaccine
RE: Retinol equivalent
RDR: relative dose response
VAD: vitamin A deficiency
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmad 2009 Supplementation for women during pregnancy.
Ala-Houhala 1988 Alternate allocation to the intervention or control groups.
Alam 2010 Provision of fat rather than vitamin A supplements.
Atalhi 2011 Provision of vitamin A rich foods rather than vitamin A supplements
Basu 2003 Alternate allocation to the intervention or control groups.
Bezerra 2009 Alternate allocation to the intervention or control groups.
Canfield 2001 Provision of vitamin A rich foods rather than vitamin A supplements
De Pee 1995 Provision of vitamin A rich foods rather than vitamin A supplements
El Hamdouchi 2013 Provision of vitamin A rich foods rather than vitamin A supplements
Filteau 1999 Provision of vitamin A rich foods rather than vitamin A supplements
Garcia 2010 Alternate allocation to the intervention or control groups.
Gossage 2000 Participants were lactating and non-lactating women (paired) whowere then randomised to either supplement
or placebo. The study was “designed to explore possible interactions between short-term β-carotene supple-
mentation and lactation on mitogenic DNA synthesis in immune-related peripheral blood T lymphocytes as
well as to determine the effects of β-carotene supplementation on concentrations of other major carotenoids
in the plasma of lactating and nonlactating women.” p.950. It was not designed to consider maternal or infant
mortality or morbidity, where were the focus of our review
Haskell 2013a Supplementation after the first 6 weeks postpartum (4-12 months postpartum)
Haskell 2013b Supplementation after the first 6 weeks postpartum (4-12 months postpartum)
Humphrey 2006 Vitamin A supplementation for women who live with HIV.
51Vitamin A supplementation for postpartum women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Khan 2007 Provision of vitamin A rich foods rather than vitamin A supplements
Lietz 2001 Provision of vitamin A rich foods rather than vitamin A supplements
Lietz 2006 Provision of vitamin A rich foods rather than vitamin A supplements
Lima 2012 Alternate allocation to the intervention or control groups.
Ncube 2001 Provision of vitamin A rich foods rather than vitamin A supplements
NNIPS-2 Long-term supplementation for women of reproductive age.
ObaapaVitA Long-term supplementation for women of reproductive age.
Swaminathan 2015 Provision of vitamin A rich foods and nutrition counselling rather than vitamin A supplements
Tchum 2006 Alternate allocation to the control or test group.
Turner 2013 Supplementation after the first 6 weeks postpartum (4-12 months postpartum)
West 2011 Long-term supplementation for women of reproductive age.
Characteristics of studies awaiting assessment [ordered by study ID]
Nga 2013
Methods Randomised, double-blind, placebo-controlled trial.
Participants Healthy women, 18 to 50 years of age, with no gemelar gestation
Hanoi, Vietnam.
N = 400 women and their infants.
Interventions 1. Single high dose of vitamin A supplementation (200,000 IU) within 3 days plus a placebo at 6 weeks postpartum.
*
2. A placebo within 3 days plus a single high dose of vitamin A supplementation (200,000 IU) at 6 weeks postpartum.
*
Outcomes Infant acute phase proteins (CRP, AGP), morbidities, nutritional status (anthropometry), hepatic vitamin A reserves
and plasma retinol concentrations. Maternal acute phase proteins, serum and breast milk retinol concentrations
Notes We emailed the author questioning about the research publications and we received no answer
*As stated in the Clinical Trials Register.
Registered at Clinical Trials Register: NCT00952640.
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Wang 2012
Methods Randomised, double-blind, placebo-controlled trial.
Participants Healthy women, negative for Hepaptitis-B antigen, with no gemelar gestation, no complicated pregnancy, no breast-
feeding restriction; infant with adequate newborn weight
Linyi, Shandong, China.
N = 150 women and their infants.
Interventions 1. 2 high doses of vitamin A supplementation (200,000 IU) at 2 weeks and 3 months (total: 400,000 IU) postpartum
plus daily doses of 10 mg alpha-tocopherol and 10 mcg cholecalciferol.*
2. Daily doses of vitamin A supplementation (4000 IU) plus daily doses of 10 mg alpha-tocopherol and 10 mcg
cholecalciferol for 6 months during postpartum.*
3. No vitamin A supplementation plus daily doses of 10mg alpha-tocopherol and 10mcg cholecalciferol for 6months
during postpartum.*
Outcomes Infant plasma anti hepatitis-B antibody, plasma retinol concentrations, plasma C-reactive protein and plasma alpha-
acid glycoprotein. Maternal plasma and breast milk retinol concentrations
Notes We emailed the author questioning about the research publications and the answer was: “The experimental results
you mentioned has not been published yet”
*As stated in the protocol register.
Chinese Clinical Trial Register: ChCTR-TRC-12001914.
AGP: alpha acid glycoprotein
CRP: C-reactive protein
IU: international unit
Characteristics of ongoing studies [ordered by study ID]
Ahmad 2015
Trial name or title Stopping postpartum vitamin A supplementation: are we missing concealed benefit?
Methods Randomised, double-blind, placebo-controlled trial.
Participants Pregnant women 18 to 32 years of age with low obstetric risk
Dhaka, Bangladesh.
N = 128 women and their infants.
Interventions 1. Single high dose of vitamin A supplementation (200,000 IU) within 3 days plus a placebo at 6 weeks
postpartum
2. A placebo within 3 days plus single high dose of vitamin A supplementation (200,000 IU) at 6 weeks
postpartum
3. 2 high doses of vitamin A supplementation (200,000 IU) within 3 days and at 6 weeks (total: 400,000 IU)
postpartum.
4. 2 placebos within 3 days and at 6 weeks postpartum.
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Ahmad 2015 (Continued)
Outcomes Breast milk sIgA, sCD14, TGF-beta, IL-7, GM-CSF, maternal plasma and breast milk retinol concentrations.
Microbial pattern recognition receptors (Toll-like receptor, TLR) and stimulated TNF-α, IL-10, and IFN-
α responses; epitope-independent mitogen (PHA) stimulated T cell polarisation: IFN-γ (Th1), IL-13 (Th2)
, IL-17 (Th17), and IL-10 (Tr1); pertussis toxin and hepatitis B surface antigen-specific and IgG antibody-
secreting plasma cell responses. Infant morbidities, anthropometry (growth and weight-for-age z-score) and
plasma retinol concentration
Starting date October, 2013.
Contact information smeahmad@icddrb.org
Notes Clinical Trials Register: NCT02043223.
IU: international unit
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D A T A A N D A N A L Y S E S
Comparison 1. Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus
control (placebo, no treatment, other)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality to 6 months 1 564 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.09, 2.71]
1.1 400,000 IU versus placebo 1 564 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.09, 2.71]
2 Maternal fever at 3 months
postpartum
Other data No numeric data
2.1 200,000 IU versus no
treatment
Other data No numeric data
3 Maternal respiratory tract
infection at 3 months
postpartum
Other data No numeric data
3.1 200,000 IU versus no
treatment
Other data No numeric data
4 Maternal diarrhoea at 3 months
postpartum
Other data No numeric data
4.1 200,000 IU versus no
treatment
Other data No numeric data
5 Maternal adverse effects of
supplementation
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Headache within 30 hours
of dosing: 400,000 IU versus
placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.74, 1.99]
5.2 Blurred vision within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.39, 6.82]
5.3 Drowsiness within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [0.91, 4.79]
5.4 Nausea within 30 hours
of dosing: 400,000 IU versus
placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.44, 4.31]
5.5 Vomiting within 30 hours
of dosing: 400,000 IU versus
placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.14]
5.6 Poor appetite within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [0.69, 7.14]
5.7 Abdominal pain within 30
hours of dosing: 400,000 IU
versus placebo
1 786 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.95, 1.73]
6 Maternal serum retinol
(mcmol/L) at 3 - 3.5 months
postpartum
5 Mean Difference (IV, Random, 95% CI) Subtotals only
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6.1 200,000 - 400,000 IU
versus placebo or no treatment
5 704 Mean Difference (IV, Random, 95% CI) 0.11 [0.03, 0.19]
6.2 200,000 - 300,000 IU
versus placebo or no treatment
4 302 Mean Difference (IV, Random, 95% CI) 0.17 [0.07, 0.26]
6.3 400,000 IU versus placebo 1 402 Mean Difference (IV, Random, 95% CI) 0.04 [-0.01, 0.09]
6.4 Beta-carotene: 7.8 mg
daily versus placebo
1 54 Mean Difference (IV, Random, 95% CI) 0.10 [-0.14, 0.34]
7 Maternal serum retinol
(mcmol/L) at 6 - 6.5 months
postpartum
4 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 200,000 - 400,000 IU
versus placebo or no treatment
4 533 Mean Difference (IV, Random, 95% CI) 0.06 [-0.06, 0.18]
7.2 200,000 - 300,000 IU
versus placebo or no treatment
3 242 Mean Difference (IV, Random, 95% CI) 0.13 [0.03, 0.23]
7.3 400,000 IU versus placebo 1 291 Mean Difference (IV, Random, 95% CI) -0.02 [-0.08, 0.04]
7.4 Beta-carotene: 7.8 mg
daily versus placebo
1 50 Mean Difference (IV, Random, 95% CI) 0.05 [-0.28, 0.38]
8 Maternal serum retinol
(mcmol/L) at 9 months
postpartum
2 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 200,000 - 300,000 IU
versus placebo or no treatment
2 98 Mean Difference (IV, Random, 95% CI) 0.00 [-0.16, 0.17]
8.2 Beta-carotene: 7.8 mg
daily versus placebo
1 51 Mean Difference (IV, Random, 95% CI) 0.19 [-0.08, 0.46]
9 Maternal low hepatic vitamin A
reserves 3 months postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 200,000 - 300,000 IU
versus placebo
2 191 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.16, 2.08]
9.2 Beta-carotene: 7.8 mg
daily versus placebo
1 54 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.43, 1.32]
10 Maternal low hepatic vitamin A
reserves 6 months postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 200,000 - 300,000 IU
versus placebo
2 192 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.48, 2.23]
10.2 Beta-carotene: 7.8 mg
daily versus placebo
1 50 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.21, 1.49]
11 Maternal low hepatic vitamin A
reserves 9 months postpartum
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 200,000 IU versus
placebo
1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.29, 1.41]
11.2 Beta-carotene: 7.8 mg
daily versus placebo
1 51 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.27, 1.30]
12 Maternal breast milk retinol
(mcmol/L) at 3 - 3.5 months
postpartum
6 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 200,000 - 400,000 IU
versus placebo no treatment
6 837 Mean Difference (IV, Random, 95% CI) 0.20 [0.08, 0.31]
12.2 200,000 - 300,000 IU
versus placebo no treatment
5 415 Mean Difference (IV, Random, 95% CI) 0.25 [0.12, 0.37]
12.3 400,000 IU versus
placebo
1 422 Mean Difference (IV, Random, 95% CI) 0.08 [0.03, 0.13]
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12.4 Beta-carotene: 7.8 mg
daily versus placebo
1 109 Mean Difference (IV, Random, 95% CI) 0.02 [-0.17, 0.21]
13 Maternal breast milk retinol
(mcmol/L) at 6 - 6.5 months
postpartum
4 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 200,000 - 400,000 IU
versus placebo or no treatment
4 645 Mean Difference (IV, Random, 95% CI) 0.20 [-0.01, 0.41]
13.2 200,000 - 300,000 IU
versus placebo or no treatment
3 291 Mean Difference (IV, Random, 95% CI) 0.28 [-0.04, 0.60]
13.3 400,000 IU versus
placebo
1 354 Mean Difference (IV, Random, 95% CI) 0.06 [0.01, 0.11]
13.4 Beta-carotene: 7.8 mg
daily versus placebo
1 104 Mean Difference (IV, Random, 95% CI) 0.12 [-0.13, 0.37]
14 Maternal breast milk retinol
(mcmol/L) at 8 - 9 months
postpartum
3 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 200,000 - 300,000 IU
versus placebo or no treatment
3 275 Mean Difference (IV, Random, 95% CI) 0.15 [-0.16, 0.45]
14.2 Beta-carotene: 7.8 mg
daily versus placebo
1 103 Mean Difference (IV, Random, 95% CI) 0.21 [0.01, 0.41]
15 Maternal breast milk retinol (<
1.05 mcmol/L) at 3 months
postpartum
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 200,000 - 300,000 IU
versus placebo or no treatment
3 304 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.37, 0.84]
15.2 Beta-carotene: 7.8 mg
daily versus placebo
1 109 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.76, 1.15]
16 Maternal breast milk retinol (<
1.05 mcmol/L) at 6 months
postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 200,000 - 300,000 IU
versus placebo
2 241 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.22, 1.94]
16.2 Beta-carotene: 7.8 mg
daily versus placebo
1 104 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.64, 1.10]
17 Maternal breast milk retinol (<
1.05 mcmol/L) at 8 - 9 months
postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 200,000 - 300,000 IU
versus placebo
2 225 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.45, 1.40]
17.2 Beta-carotene: 7.8mg
daily versus placebo
1 103 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.62, 1.03]
18 Maternal breast milk retinol
(< 0.28 mcmol/g of fat) at 3
months postpartum
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 200,000 IU versus
placebo
1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.60, 1.07]
18.2 Beta-carotene: 7.8 mg
daily versus placebo
1 109 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.79, 1.29]
19 Maternal breast milk retinol
(< 0.28 mcmol/g of fat) at 6
months postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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19.1 200,000 IU versus
placebo
2 779 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.72, 1.01]
19.2 Beta-carotene: 7.8 mg
daily versus placebo
1 104 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.69, 1.12]
20 Maternal breast milk retinol
(< 0.28 mcmol/g of fat) at 9
months postpartum
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 200,000 IU versus
placebo
2 667 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.73, 1.04]
20.2 Beta-carotene: 7.8 mg
daily versus placebo
1 102 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.60, 0.97]
21 Maternal abnormal
conjunctival impression
cytology 3 months postpartum
1 148 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.55, 1.80]
21.1 300,000 IU versus
placebo
1 148 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.55, 1.80]
22 Maternal abnormal
conjunctival impression
cytology 6 months postpartum
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 300,000 IU versus
placebo
1 142 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.27, 1.17]
23 Infant mortality 5 6090 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.77, 1.52]
23.1 Deaths to 14 weeks:
400,000 IU versus placebo
1 279 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.33, 1.54]
23.2 Deaths to 12 months:
300,000 IU versus placebo
1 598 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.34, 2.24]
23.3 Death to 6 months:
200,000 IU versus placebo
1 546 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [0.26, 9.17]
23.4 Deaths to 12 months:
400,000 IU versus placebo
1 4601 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.83, 1.98]
23.5 Deaths to 2 months:
200,000 IU versus placebo
1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.90]
24 Infant diarrhoea (one or more
episodes) to 12 months
1 456 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.98, 1.06]
24.1 300,000 IU versus
placebo
1 456 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.98, 1.06]
25 Infant diarrhoea episodes and
duration
Other data No numeric data
25.1 200,000 IU versus no
treatment
Other data No numeric data
26 Infant gastroenteritis to 3
months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
26.1 200,000 IU versus no
treatment
1 84 Risk Ratio (M-H, Fixed, 95% CI) 6.03 [0.30, 121.82]
27 Infant acute respiratory
infection (one or more
episodes) to 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
27.1 300,000 IU versus
placebo
1 456 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.96, 1.03]
28 Infant upper respiratory tract
infection to 3 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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28.1 200,000 IU versus
treatment
1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.22, 3.81]
29 Infant acute respiratory tract
infection episodes and duration
Other data No numeric data
29.1 200,000 IU versus no
treatment
Other data No numeric data
30 Infant febrile illness episodes Other data No numeric data
30.1 200,000 IU versus no
treatment
Other data No numeric data
31 Infant adverse effects of
supplementation
1 444 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.61, 6.55]
31.1 Bulging fontanelle:
400,000 IU versus placebo
1 444 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.61, 6.55]
32 Infant serum retinol (mcmol/L)
at 3 - 3.5 months postpartum
4 Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 200,000 - 400,000 IU
versus no treatment
4 379 Mean Difference (IV, Random, 95% CI) 0.11 [-0.05, 0.26]
32.2 200,000 IU versus
placebo or no treatment
3 215 Mean Difference (IV, Random, 95% CI) 0.20 [0.00, 0.39]
32.3 400,000 IU versus
placebo
1 164 Mean Difference (IV, Random, 95% CI) 0.02 [-0.03, 0.07]
33 Infant serum retinol (mcmol/L)
at 6 - 6.5 months postpartum
4 Mean Difference (IV, Random, 95% CI) Subtotals only
33.1 200,000 - 400,000 IU
versus placebo
4 430 Mean Difference (IV, Random, 95% CI) 0.04 [-0.00, 0.09]
33.2 200,000 - 300,000 IU
versus placebo
3 289 Mean Difference (IV, Random, 95% CI) 0.03 [-0.02, 0.09]
33.3 Beta-carotene: 7.8 mg
daily versus placebo
1 104 Mean Difference (IV, Random, 95% CI) 0.03 [-0.06, 0.12]
33.4 400,00 IU versus placebo 1 141 Mean Difference (IV, Random, 95% CI) 0.06 [-0.02, 0.14]
34 Infant low hepatic vitamin
A reserves at 6 - 6.5 months
postpartum
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
34.1 200,000 - 400,000 IU
versus placebo
3 424 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.78, 1.15]
34.2 200,000 - 300,000 IU
versus placebo
2 235 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.22, 2.05]
34.3 400,000 IU versus
placebo
1 189 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.90, 1.22]
34.4 Beta-carotene: 7.8 mg
daily versus placebo
1 104 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.02]
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Comparison 2. Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal serum retinol
(mcmol/L)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 400,000 IU versus
200,000 IU at 2 months
postpartum
2 429 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.06, 0.14]
1.2 400,000 IU versus
200,000 IU at 4 months
postpartum
1 213 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.29, 0.05]
1.3 400,000 IU versus
200,000 IU at 6 months
postpartum
1 200 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.24, 0.08]
2 Maternal breast milk retinol
(mcmol/L)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 400,000 IU versus
200,000 IU at 2 months
postpartum
2 377 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.14, 0.11]
2.2 400,000 IU versus
200,000 IU at 3 months
postpartum
1 190 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.28, 0.16]
2.3 400,000 IU versus
200,000 IU at 4 months
postpartum
2 348 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.13, 0.08]
2.4 400,000 IU versus
200,000 IU at 6 months
postpartum
1 192 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.13, 0.31]
3 Maternal breast milk retinol (<
1.05 mcmol/L)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 400,000 IU versus
200,000 IU at 3 months
postpartum
1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.72, 2.17]
3.2 400,000 IU versus
200,000 IU at 6 months
postpartum
1 192 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.53, 1.25]
4 Infant serum retinol (mcmol/L ) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 400,000 IU versus
200,000 IU at 2 months
postpartum
2 362 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.05, 0.07]
4.2 400,000 IU versus
200,000 IU at 4 months
postpartum
1 192 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.20, 0.14]
4.3 400,000 IU versus
200,000 IU at 6 months
postpartum
1 173 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.23, 0.11]
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Analysis 1.1. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 1 Maternal mortality to 6 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 1 Maternal mortality to 6 months
Study or subgroup Vitamin A Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 400,000 IU versus placebo
Ayah 2007 2/282 4/282 100.0 % 0.50 [ 0.09, 2.71 ]
Total (95% CI) 282 282 100.0 % 0.50 [ 0.09, 2.71 ]
Total events: 2 (Vitamin A), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 1.2. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 2 Maternal fever at 3 months postpartum.
Maternal fever at 3 months postpartum
Study Outcome Supplement Control P value
200,000 IU versus no treatment
Roy 1997 Number of cumulative
episodes;
(cumulative duration of ill-
ness in days)
10 (30);
n = 25
10 (28);
n = 25
Report states no significant difference
Analysis 1.3. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 3 Maternal respiratory tract infection at 3
months postpartum.
Maternal respiratory tract infection at 3 months postpartum
Study Outcome Supplement Control P value
200,000 IU versus no treatment
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Maternal respiratory tract infection at 3 months postpartum (Continued)
Roy 1997 Number of cumulative
episodes;
(cumulative duration of ill-
ness in days)
23 (82);
n = 25
25 (125);
n = 25
Report states no significant difference
Roy 1997
Analysis 1.4. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 4 Maternal diarrhoea at 3 months
postpartum.
Maternal diarrhoea at 3 months postpartum
Study Outcome Vitamin A Control P value
200,000 IU versus no treatment
Roy 1997 Number of cumulative
episodes;
(cumulative duration of ill-
ness in days)
10 (27);
n = 25
2 (15);
n = 25
Report states no significant difference
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Analysis 1.5. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 5 Maternal adverse effects of
supplementation.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 5 Maternal adverse effects of supplementation
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 32/396 26/390 100.0 % 1.21 [ 0.74, 1.99 ]
Subtotal (95% CI) 396 390 100.0 % 1.21 [ 0.74, 1.99 ]
Total events: 32 (Supplement), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 Blurred vision within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 5/396 3/390 100.0 % 1.64 [ 0.39, 6.82 ]
Subtotal (95% CI) 396 390 100.0 % 1.64 [ 0.39, 6.82 ]
Total events: 5 (Supplement), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Drowsiness within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 17/396 8/390 100.0 % 2.09 [ 0.91, 4.79 ]
Subtotal (95% CI) 396 390 100.0 % 2.09 [ 0.91, 4.79 ]
Total events: 17 (Supplement), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
4 Nausea within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 7/396 5/390 100.0 % 1.38 [ 0.44, 4.31 ]
Subtotal (95% CI) 396 390 100.0 % 1.38 [ 0.44, 4.31 ]
Total events: 7 (Supplement), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
5 Vomiting within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 1/396 3/390 100.0 % 0.33 [ 0.03, 3.14 ]
Subtotal (95% CI) 396 390 100.0 % 0.33 [ 0.03, 3.14 ]
Total events: 1 (Supplement), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
6 Poor appetite within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 9/396 4/390 100.0 % 2.22 [ 0.69, 7.14 ]
Subtotal (95% CI) 396 390 100.0 % 2.22 [ 0.69, 7.14 ]
0.02 0.1 1 10 50
Favours supplement Favours placebo
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(. . . Continued)
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 9 (Supplement), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
7 Abdominal pain within 30 hours of dosing: 400,000 IU versus placebo
ZVITAMBO Study Group 82/396 63/390 100.0 % 1.28 [ 0.95, 1.73 ]
Subtotal (95% CI) 396 390 100.0 % 1.28 [ 0.95, 1.73 ]
Total events: 82 (Supplement), 63 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
0.02 0.1 1 10 50
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Analysis 1.6. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 6 Maternal serum retinol (mcmol/L) at 3 -
3.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 6 Maternal serum retinol (mcmol/L) at 3 - 3.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 400,000 IU versus placebo or no treatment
Ayah 2007 205 1.05 (0.22) 197 1.01 (0.29) 44.0 % 0.04 [ -0.01, 0.09 ]
Martins 2010 31 1.17 (0.34) 30 1.02 (0.28) 17.9 % 0.15 [ -0.01, 0.31 ]
RETIBETA Project 34 1.45 (0.47) 18 1.33 (0.42) 8.7 % 0.12 [ -0.13, 0.37 ]
Roy 1997 25 1.59 (0.39) 25 1.33 (0.39) 11.1 % 0.26 [ 0.04, 0.48 ]
Stoltzfus 1993a 70 1.39 (0.49) 69 1.24 (0.43) 18.3 % 0.15 [ 0.00, 0.30 ]
Subtotal (95% CI) 365 339 100.0 % 0.11 [ 0.03, 0.19 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.53, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 2.69 (P = 0.0071)
2 200,000 - 300,000 IU versus placebo or no treatment
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(. . . Continued)
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Martins 2010 31 1.17 (0.34) 30 1.02 (0.28) 33.9 % 0.15 [ -0.01, 0.31 ]
RETIBETA Project 34 1.45 (0.47) 18 1.33 (0.42) 13.2 % 0.12 [ -0.13, 0.37 ]
Roy 1997 25 1.59 (0.39) 25 1.33 (0.39) 17.7 % 0.26 [ 0.04, 0.48 ]
Stoltzfus 1993a 70 1.39 (0.49) 69 1.24 (0.43) 35.2 % 0.15 [ 0.00, 0.30 ]
Subtotal (95% CI) 160 142 100.0 % 0.17 [ 0.07, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.57 (P = 0.00036)
3 400,000 IU versus placebo
Ayah 2007 205 1.05 (0.22) 197 1.01 (0.29) 100.0 % 0.04 [ -0.01, 0.09 ]
Subtotal (95% CI) 205 197 100.0 % 0.04 [ -0.01, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
4 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 36 1.43 (0.43) 18 1.33 (0.42) 100.0 % 0.10 [ -0.14, 0.34 ]
Subtotal (95% CI) 36 18 100.0 % 0.10 [ -0.14, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 6.41, df = 3 (P = 0.09), I2 =53%
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Analysis 1.7. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 7 Maternal serum retinol (mcmol/L) at 6 -
6.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 7 Maternal serum retinol (mcmol/L) at 6 - 6.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 400,000 IU versus placebo or no treatment
Ayah 2007 148 0.96 (0.25) 143 0.98 (0.24) 42.1 % -0.02 [ -0.08, 0.04 ]
RETIBETA Project 35 1.47 (0.38) 18 1.52 (0.56) 12.8 % -0.05 [ -0.34, 0.24 ]
Roy 1997 25 1.54 (0.65) 25 1.36 (0.34) 12.9 % 0.18 [ -0.11, 0.47 ]
Stoltzfus 1993a 67 1.23 (0.34) 72 1.08 (0.37) 32.2 % 0.15 [ 0.03, 0.27 ]
Subtotal (95% CI) 275 258 100.0 % 0.06 [ -0.06, 0.18 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 7.97, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 0.91 (P = 0.36)
2 200,000 - 300,000 IU versus placebo or no treatment
RETIBETA Project 35 1.47 (0.38) 18 1.52 (0.56) 12.6 % -0.05 [ -0.34, 0.24 ]
Roy 1997 25 1.54 (0.65) 25 1.36 (0.34) 12.6 % 0.18 [ -0.11, 0.47 ]
Stoltzfus 1993a 67 1.23 (0.34) 72 1.08 (0.37) 74.8 % 0.15 [ 0.03, 0.27 ]
Subtotal (95% CI) 127 115 100.0 % 0.13 [ 0.03, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.73, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
3 400,000 IU versus placebo
Ayah 2007 148 0.96 (0.25) 143 0.98 (0.24) 100.0 % -0.02 [ -0.08, 0.04 ]
Subtotal (95% CI) 148 143 100.0 % -0.02 [ -0.08, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
4 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 32 1.57 (0.59) 18 1.52 (0.56) 100.0 % 0.05 [ -0.28, 0.38 ]
Subtotal (95% CI) 32 18 100.0 % 0.05 [ -0.28, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 6.67, df = 3 (P = 0.08), I2 =55%
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Analysis 1.8. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 8 Maternal serum retinol (mcmol/L) at 9
months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 8 Maternal serum retinol (mcmol/L) at 9 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 300,000 IU versus placebo or no treatment
RETIBETA Project 32 1.47 (0.46) 16 1.36 (0.45) 36.9 % 0.11 [ -0.16, 0.38 ]
Roy 1997 25 1.29 (0.39) 25 1.35 (0.36) 63.1 % -0.06 [ -0.27, 0.15 ]
Subtotal (95% CI) 57 41 100.0 % 0.00 [ -0.16, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 35 1.55 (0.47) 16 1.36 (0.45) 100.0 % 0.19 [ -0.08, 0.46 ]
Subtotal (95% CI) 35 16 100.0 % 0.19 [ -0.08, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Chi2 = 1.34, df = 1 (P = 0.25), I2 =26%
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Analysis 1.9. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 9 Maternal low hepatic vitamin A reserves
3 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 9 Maternal low hepatic vitamin A reserves 3 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 - 300,000 IU versus placebo
RETIBETA Project 6/34 10/18 52.9 % 0.32 [ 0.14, 0.73 ]
Stoltzfus 1993a 7/70 6/69 47.1 % 1.15 [ 0.41, 3.25 ]
Subtotal (95% CI) 104 87 100.0 % 0.58 [ 0.16, 2.08 ]
Total events: 13 (Supplement), 16 (Placebo)
Heterogeneity: Tau2 = 0.62; Chi2 = 3.67, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 15/36 10/18 100.0 % 0.75 [ 0.43, 1.32 ]
Subtotal (95% CI) 36 18 100.0 % 0.75 [ 0.43, 1.32 ]
Total events: 15 (Supplement), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
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Analysis 1.10. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 10 Maternal low hepatic vitamin A
reserves 6 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 10 Maternal low hepatic vitamin A reserves 6 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 - 300,000 IU versus placebo
RETIBETA Project 11/35 6/18 89.5 % 0.94 [ 0.42, 2.13 ]
Stoltzfus 1993a 2/67 1/72 10.5 % 2.15 [ 0.20, 23.16 ]
Subtotal (95% CI) 102 90 100.0 % 1.03 [ 0.48, 2.23 ]
Total events: 13 (Supplement), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 6/32 6/18 100.0 % 0.56 [ 0.21, 1.49 ]
Subtotal (95% CI) 32 18 100.0 % 0.56 [ 0.21, 1.49 ]
Total events: 6 (Supplement), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Chi2 = 0.91, df = 1 (P = 0.34), I2 =0.0%
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Analysis 1.11. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 11 Maternal low hepatic vitamin A
reserves 9 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 11 Maternal low hepatic vitamin A reserves 9 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
RETIBETA Project 9/32 7/16 100.0 % 0.64 [ 0.29, 1.41 ]
Subtotal (95% CI) 32 16 100.0 % 0.64 [ 0.29, 1.41 ]
Total events: 9 (Supplement), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 9/35 7/16 100.0 % 0.59 [ 0.27, 1.30 ]
Subtotal (95% CI) 35 16 100.0 % 0.59 [ 0.27, 1.30 ]
Total events: 9 (Supplement), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.87), I2 =0.0%
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Analysis 1.12. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 12 Maternal breast milk retinol (mcmol/L)
at 3 - 3.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 12 Maternal breast milk retinol (mcmol/L) at 3 - 3.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 400,000 IU versus placebo no treatment
Ayah 2007 221 0.52 (0.23) 201 0.44 (0.28) 35.6 % 0.08 [ 0.03, 0.13 ]
Martins 2010 31 1.56 (0.57) 30 1.34 (0.89) 7.5 % 0.22 [ -0.16, 0.60 ]
RETIBETA Project 69 1.2 (1) 36 0.83 (0.43) 12.0 % 0.37 [ 0.10, 0.64 ]
Roy 1997 25 1.34 (0.53) 25 1.12 (0.51) 11.2 % 0.22 [ -0.07, 0.51 ]
Stoltzfus 1993a 57 2.45 (1.23) 60 1.82 (1.28) 5.5 % 0.63 [ 0.18, 1.08 ]
Vinutha 2000 36 1.09 (0.26) 46 0.92 (0.24) 28.3 % 0.17 [ 0.06, 0.28 ]
Subtotal (95% CI) 439 398 100.0 % 0.20 [ 0.08, 0.31 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.93, df = 5 (P = 0.04); I2 =58%
Test for overall effect: Z = 3.35 (P = 0.00080)
2 200,000 - 300,000 IU versus placebo no treatment
Martins 2010 31 1.56 (0.57) 30 1.34 (0.89) 9.7 % 0.22 [ -0.16, 0.60 ]
RETIBETA Project 69 1.2 (1) 36 0.83 (0.43) 16.5 % 0.37 [ 0.10, 0.64 ]
Roy 1997 25 1.34 (0.53) 25 1.12 (0.51) 15.3 % 0.22 [ -0.07, 0.51 ]
Stoltzfus 1993a 57 2.45 (1.23) 60 1.82 (1.28) 6.9 % 0.63 [ 0.18, 1.08 ]
Vinutha 2000 36 1.09 (0.26) 46 0.92 (0.24) 51.6 % 0.17 [ 0.06, 0.28 ]
Subtotal (95% CI) 218 197 100.0 % 0.25 [ 0.12, 0.37 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.07, df = 4 (P = 0.28); I2 =21%
Test for overall effect: Z = 3.90 (P = 0.000097)
3 400,000 IU versus placebo
Ayah 2007 221 0.52 (0.23) 201 0.44 (0.28) 100.0 % 0.08 [ 0.03, 0.13 ]
Subtotal (95% CI) 221 201 100.0 % 0.08 [ 0.03, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
4 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 73 0.85 (0.55) 36 0.83 (0.43) 100.0 % 0.02 [ -0.17, 0.21 ]
Subtotal (95% CI) 73 36 100.0 % 0.02 [ -0.17, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Chi2 = 9.16, df = 3 (P = 0.03), I2 =67%
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Analysis 1.13. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 13 Maternal breast milk retinol (mcmol/L)
at 6 - 6.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 13 Maternal breast milk retinol (mcmol/L) at 6 - 6.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 400,000 IU versus placebo or no treatment
Ayah 2007 184 0.5 (0.21) 170 0.44 (0.27) 33.4 % 0.06 [ 0.01, 0.11 ]
RETIBETA Project 70 0.85 (0.53) 35 0.87 (0.61) 23.7 % -0.02 [ -0.26, 0.22 ]
Roy 1997 25 1.06 (0.46) 25 0.73 (0.22) 26.0 % 0.33 [ 0.13, 0.53 ]
Stoltzfus 1993a 66 2.36 (1.17) 70 1.77 (0.97) 16.9 % 0.59 [ 0.23, 0.95 ]
Subtotal (95% CI) 345 300 100.0 % 0.20 [ -0.01, 0.41 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 14.90, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 1.88 (P = 0.060)
2 200,000 - 300,000 IU versus placebo or no treatment
RETIBETA Project 70 0.85 (0.53) 35 0.87 (0.61) 35.1 % -0.02 [ -0.26, 0.22 ]
Roy 1997 25 1.06 (0.46) 25 0.73 (0.22) 37.2 % 0.33 [ 0.13, 0.53 ]
Stoltzfus 1993a 66 2.36 (1.17) 70 1.77 (0.97) 27.7 % 0.59 [ 0.23, 0.95 ]
Subtotal (95% CI) 161 130 100.0 % 0.28 [ -0.04, 0.60 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 8.97, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 1.73 (P = 0.083)
3 400,000 IU versus placebo
Ayah 2007 184 0.5 (0.21) 170 0.44 (0.27) 100.0 % 0.06 [ 0.01, 0.11 ]
Subtotal (95% CI) 184 170 100.0 % 0.06 [ 0.01, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
4 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 69 0.99 (0.62) 35 0.87 (0.61) 100.0 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 69 35 100.0 % 0.12 [ -0.13, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 3.46, df = 3 (P = 0.33), I2 =13%
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Analysis 1.14. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 14 Maternal breast milk retinol (mcmol/L)
at 8 - 9 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 14 Maternal breast milk retinol (mcmol/L) at 8 - 9 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 300,000 IU versus placebo or no treatment
RETIBETA Project 64 0.91 (0.68) 33 0.79 (0.44) 41.6 % 0.12 [ -0.10, 0.34 ]
Roy 1997 25 0.94 (0.44) 25 1.09 (0.87) 29.1 % -0.15 [ -0.53, 0.23 ]
Stoltzfus 1993a 63 2.04 (1.19) 65 1.56 (0.99) 29.3 % 0.48 [ 0.10, 0.86 ]
Subtotal (95% CI) 152 123 100.0 % 0.15 [ -0.16, 0.45 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 5.32, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 70 1 (0.58) 33 0.79 (0.44) 100.0 % 0.21 [ 0.01, 0.41 ]
Subtotal (95% CI) 70 33 100.0 % 0.21 [ 0.01, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 1.15. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 15 Maternal breast milk retinol (< 1.05
mcmol/L) at 3 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 15 Maternal breast milk retinol (< 1.05 mcmol/L) at 3 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 - 300,000 IU versus placebo or no treatment
RETIBETA Project 39/69 29/36 49.3 % 0.70 [ 0.54, 0.91 ]
Stoltzfus 1993a 6/57 19/60 17.0 % 0.33 [ 0.14, 0.77 ]
Vinutha 2000 13/36 32/46 33.7 % 0.52 [ 0.32, 0.83 ]
Subtotal (95% CI) 162 142 100.0 % 0.56 [ 0.37, 0.84 ]
Total events: 58 (Supplement), 80 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.40, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 2.80 (P = 0.0051)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 55/73 29/36 100.0 % 0.94 [ 0.76, 1.15 ]
Subtotal (95% CI) 73 36 100.0 % 0.94 [ 0.76, 1.15 ]
Total events: 55 (Supplement), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 4.88, df = 1 (P = 0.03), I2 =80%
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Analysis 1.16. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 16 Maternal breast milk retinol (< 1.05
mcmol/L) at 6 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 16 Maternal breast milk retinol (< 1.05 mcmol/L) at 6 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 - 300,000 IU versus placebo
RETIBETA Project 51/70 26/35 57.1 % 0.98 [ 0.77, 1.25 ]
Stoltzfus 1993a 6/66 17/70 42.9 % 0.37 [ 0.16, 0.89 ]
Subtotal (95% CI) 136 105 100.0 % 0.65 [ 0.22, 1.94 ]
Total events: 57 (Supplement), 43 (Placebo)
Heterogeneity: Tau2 = 0.53; Chi2 = 6.05, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 43/69 26/35 100.0 % 0.84 [ 0.64, 1.10 ]
Subtotal (95% CI) 69 35 100.0 % 0.84 [ 0.64, 1.10 ]
Total events: 43 (Supplement), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.66), I2 =0.0%
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Analysis 1.17. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 17 Maternal breast milk retinol (< 1.05
mcmol/L) at 8 - 9 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 17 Maternal breast milk retinol (< 1.05 mcmol/L) at 8 - 9 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 - 300,000 IU versus placebo
RETIBETA Project 48/64 26/33 65.3 % 0.95 [ 0.76, 1.19 ]
Stoltzfus 1993a 10/63 18/65 34.7 % 0.57 [ 0.29, 1.14 ]
Subtotal (95% CI) 127 98 100.0 % 0.80 [ 0.45, 1.40 ]
Total events: 58 (Supplement), 44 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 2.64, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Beta-carotene: 7.8mg daily versus placebo
RETIBETA Project 44/70 26/33 100.0 % 0.80 [ 0.62, 1.03 ]
Subtotal (95% CI) 70 33 100.0 % 0.80 [ 0.62, 1.03 ]
Total events: 44 (Supplement), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 1.18. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 18 Maternal breast milk retinol (< 0.28
mcmol/g of fat) at 3 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 18 Maternal breast milk retinol (< 0.28 mcmol/g of fat) at 3 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus placebo
RETIBETA Project 40/69 26/36 100.0 % 0.80 [ 0.60, 1.07 ]
Subtotal (95% CI) 69 36 100.0 % 0.80 [ 0.60, 1.07 ]
Total events: 40 (Supplement), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 53/73 26/36 100.0 % 1.01 [ 0.79, 1.29 ]
Subtotal (95% CI) 73 36 100.0 % 1.01 [ 0.79, 1.29 ]
Total events: 53 (Supplement), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 1.37, df = 1 (P = 0.24), I2 =27%
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Analysis 1.19. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 19 Maternal breast milk retinol (< 0.28
mcmol/g of fat) at 6 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 19 Maternal breast milk retinol (< 0.28 mcmol/g of fat) at 6 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 IU versus placebo
RETIBETA Project 48/70 27/35 48.7 % 0.89 [ 0.70, 1.13 ]
WHO/CHD IVASSG 91/340 109/334 51.3 % 0.82 [ 0.65, 1.04 ]
Subtotal (95% CI) 410 369 100.0 % 0.85 [ 0.72, 1.01 ]
Total events: 139 (Supplement), 136 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 47/69 27/35 100.0 % 0.88 [ 0.69, 1.12 ]
Subtotal (95% CI) 69 35 100.0 % 0.88 [ 0.69, 1.12 ]
Total events: 47 (Supplement), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 1.20. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 20 Maternal breast milk retinol (< 0.28
mcmol/g of fat) at 9 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 20 Maternal breast milk retinol (< 0.28 mcmol/g of fat) at 9 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 IU versus placebo
RETIBETA Project 43/64 27/33 55.3 % 0.82 [ 0.65, 1.04 ]
WHO/CHD IVASSG 76/276 86/294 44.7 % 0.94 [ 0.72, 1.22 ]
Subtotal (95% CI) 340 327 100.0 % 0.87 [ 0.73, 1.04 ]
Total events: 119 (Supplement), 113 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 43/69 27/33 100.0 % 0.76 [ 0.60, 0.97 ]
Subtotal (95% CI) 69 33 100.0 % 0.76 [ 0.60, 0.97 ]
Total events: 43 (Supplement), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Chi2 = 0.79, df = 1 (P = 0.37), I2 =0.0%
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Analysis 1.21. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 21 Maternal abnormal conjunctival
impression cytology 3 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 21 Maternal abnormal conjunctival impression cytology 3 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Stoltzfus 1993a 17/74 17/74 100.0 % 1.00 [ 0.55, 1.80 ]
Total (95% CI) 74 74 100.0 % 1.00 [ 0.55, 1.80 ]
Total events: 17 (Supplement), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 22 Maternal abnormal conjunctival
impression cytology 6 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 22 Maternal abnormal conjunctival impression cytology 6 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Stoltzfus 1993a 9/69 17/73 100.0 % 0.56 [ 0.27, 1.17 ]
Subtotal (95% CI) 69 73 100.0 % 0.56 [ 0.27, 1.17 ]
Total events: 9 (Supplement), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 1.23. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 23 Infant mortality.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 23 Infant mortality
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deaths to 14 weeks: 400,000 IU versus placebo
Ayah 2007 10/140 14/139 22.5 % 0.71 [ 0.33, 1.54 ]
Subtotal (95% CI) 140 139 22.5 % 0.71 [ 0.33, 1.54 ]
Total events: 10 (Supplement), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
2 Deaths to 12 months: 300,000 IU versus placebo
Venkatarao 1996 8/301 9/297 14.5 % 0.88 [ 0.34, 2.24 ]
Subtotal (95% CI) 301 297 14.5 % 0.88 [ 0.34, 2.24 ]
Total events: 8 (Supplement), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
3 Death to 6 months: 200,000 IU versus placebo
Newton 2005 3/269 2/277 3.2 % 1.54 [ 0.26, 9.17 ]
Subtotal (95% CI) 269 277 3.2 % 1.54 [ 0.26, 9.17 ]
Total events: 3 (Supplement), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
4 Deaths to 12 months: 400,000 IU versus placebo
ZVITAMBO Study Group 46/2296 36/2305 57.5 % 1.28 [ 0.83, 1.98 ]
Subtotal (95% CI) 2296 2305 57.5 % 1.28 [ 0.83, 1.98 ]
Total events: 46 (Supplement), 36 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
5 Deaths to 2 months: 200,000 IU versus placebo
Martins 2010 0/33 1/33 2.4 % 0.33 [ 0.01, 7.90 ]
Subtotal (95% CI) 33 33 2.4 % 0.33 [ 0.01, 7.90 ]
Total events: 0 (Supplement), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 3039 3051 100.0 % 1.08 [ 0.77, 1.52 ]
Total events: 67 (Supplement), 62 (Placebo)
Heterogeneity: Chi2 = 2.61, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 2.61, df = 4 (P = 0.63), I2 =0.0%
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Analysis 1.24. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 24 Infant diarrhoea (one or more
episodes) to 12 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 24 Infant diarrhoea (one or more episodes) to 12 months
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Venkatarao 1996 221/228 216/228 100.0 % 1.02 [ 0.98, 1.06 ]
Total (95% CI) 228 228 100.0 % 1.02 [ 0.98, 1.06 ]
Total events: 221 (Supplement), 216 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 25 Infant diarrhoea episodes and duration.
Infant diarrhoea episodes and duration
Study Outcome Supplement No treatment Significance
200,000 IU versus no treatment
Roy 1997 Diarrhoea episodes
(mean episodes per child-
week of observation)
0.12 (95% CI 0.09 to 0.15) 0.11 (95% CI 0.08 to 0.14) P = 0.59
Roy 1997 Diarrhoea duration
(duration (days) per child-
week of observation)
0.74 (95% CI 0.53 to 0.95) 0.71 (95% CI 0.50 to 0.92) P = 0.78
Roy 1997 Child-weeks 515 522
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Analysis 1.26. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 26 Infant gastroenteritis to 3 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 26 Infant gastroenteritis to 3 months
Study or subgroup Supplement Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus no treatment
Vinutha 2000 2/38 0/46 100.0 % 6.03 [ 0.30, 121.82 ]
Subtotal (95% CI) 38 46 100.0 % 6.03 [ 0.30, 121.82 ]
Total events: 2 (Supplement), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 1.27. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 27 Infant acute respiratory infection (one
or more episodes) to 12 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 27 Infant acute respiratory infection (one or more episodes) to 12 months
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 300,000 IU versus placebo
Venkatarao 1996 218/228 219/228 100.0 % 1.00 [ 0.96, 1.03 ]
Subtotal (95% CI) 228 228 100.0 % 1.00 [ 0.96, 1.03 ]
Total events: 218 (Supplement), 219 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.81)
0.5 0.7 1 1.5 2
Favours supplement Favours placebo
83Vitamin A supplementation for postpartum women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.28. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 28 Infant upper respiratory tract infection
to 3 months.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 28 Infant upper respiratory tract infection to 3 months
Study or subgroup Supplement Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200,000 IU versus treatment
Vinutha 2000 3/38 4/46 100.0 % 0.91 [ 0.22, 3.81 ]
Subtotal (95% CI) 38 46 100.0 % 0.91 [ 0.22, 3.81 ]
Total events: 3 (Supplement), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
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Analysis 1.29. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 29 Infant acute respiratory tract infection
episodes and duration.
Infant acute respiratory tract infection episodes and duration
Study Outcome / Details Vitamin A Control Significance
200,000 IU versus no treatment
Roy 1997 Acute respiratory tract infec-
tion episodes
(mean episodes per child-
week of observation)
0.42 (95% CI 0.38 to 0.46) 0.45 (95% CI 0.41 to 0.49) P = 0.51
Roy 1997 Acute respiratory tract infec-
tion duration
(duration (days) per child-
week of observation)
3.1 (95% CI 2.7 to 3.5) 3.7 (95% CI 3.25 to 4.15) P = 0.03
Roy 1997 Child-weeks 515 522
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Analysis 1.30. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 30 Infant febrile illness episodes.
Infant febrile illness episodes
Study Outcome / Details Vitamin A Control Significance
200,000 IU versus no treatment
Roy 1997 Febrile illness episodes
(mean episodes per child-
week of observation)
0.1 (95% CI 0.09 to 0.11) 0.3 (95% CI 0.27 to 0.30) P < 0.002
Roy 1997 Child-weeks 515 522
Analysis 1.31. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 31 Infant adverse effects of
supplementation.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 31 Infant adverse effects of supplementation
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bulging fontanelle: 400,000 IU versus placebo
Ayah 2007 8/222 4/222 100.0 % 2.00 [ 0.61, 6.55 ]
Total (95% CI) 222 222 100.0 % 2.00 [ 0.61, 6.55 ]
Total events: 8 (Supplement), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 32 Infant serum retinol (mcmol/L) at 3 -
3.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 32 Infant serum retinol (mcmol/L) at 3 - 3.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 400,000 IU versus no treatment
Ayah 2007 78 0.92 (0.18) 86 0.9 (0.14) 29.9 % 0.02 [ -0.03, 0.07 ]
Bhaskaram 2000 49 0.94 (0.55) 40 0.89 (0.51) 18.7 % 0.05 [ -0.17, 0.27 ]
Martins 2010 30 0.69 (0.26) 29 0.64 (0.3) 24.2 % 0.05 [ -0.09, 0.19 ]
Vinutha 2000 38 1.06 (0.21) 29 0.77 (0.2) 27.3 % 0.29 [ 0.19, 0.39 ]
Subtotal (95% CI) 195 184 100.0 % 0.11 [ -0.05, 0.26 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 23.04, df = 3 (P = 0.00004); I2 =87%
Test for overall effect: Z = 1.38 (P = 0.17)
2 200,000 IU versus placebo or no treatment
Bhaskaram 2000 49 0.94 (0.55) 40 0.89 (0.51) 38.0 % 0.05 [ -0.17, 0.27 ]
Martins 2010 30 0.69 (26) 29 0.64 (0.3) 0.0 % 0.05 [ -9.25, 9.35 ]
Vinutha 2000 38 1.06 (0.21) 29 0.77 (0.2) 61.9 % 0.29 [ 0.19, 0.39 ]
Subtotal (95% CI) 117 98 100.0 % 0.20 [ 0.00, 0.39 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.79, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 1.99 (P = 0.047)
3 400,000 IU versus placebo
Ayah 2007 78 0.92 (0.18) 86 0.9 (0.14) 100.0 % 0.02 [ -0.03, 0.07 ]
Subtotal (95% CI) 78 86 100.0 % 0.02 [ -0.03, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 3.87, df = 2 (P = 0.14), I2 =48%
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Analysis 1.33. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 33 Infant serum retinol (mcmol/L) at 6 -
6.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 33 Infant serum retinol (mcmol/L) at 6 - 6.5 months postpartum
Study or subgroup Supplement Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 200,000 - 400,000 IU versus placebo
Ayah 2007 75 1.08 (0.31) 66 1.02 (0.17) 31.4 % 0.06 [ -0.02, 0.14 ]
Bhaskaram 2000 22 0.81 (0.35) 25 0.88 (0.31) 5.7 % -0.07 [ -0.26, 0.12 ]
RETIBETA Project 69 0.84 (0.23) 35 0.77 (0.21) 26.7 % 0.07 [ -0.02, 0.16 ]
Stoltzfus 1993a 68 0.67 (0.19) 70 0.65 (0.26) 36.1 % 0.02 [ -0.06, 0.10 ]
Subtotal (95% CI) 234 196 100.0 % 0.04 [ 0.00, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.23, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
2 200,000 - 300,000 IU versus placebo
Bhaskaram 2000 22 0.81 (0.35) 25 0.88 (0.31) 8.4 % -0.07 [ -0.26, 0.12 ]
RETIBETA Project 69 0.84 (0.23) 35 0.77 (0.21) 38.9 % 0.07 [ -0.02, 0.16 ]
Stoltzfus 1993a 68 0.67 (0.19) 70 0.65 (0.26) 52.7 % 0.02 [ -0.06, 0.10 ]
Subtotal (95% CI) 159 130 100.0 % 0.03 [ -0.02, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.26)
3 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 69 0.8 (0.22) 35 0.77 (0.21) 100.0 % 0.03 [ -0.06, 0.12 ]
Subtotal (95% CI) 69 35 100.0 % 0.03 [ -0.06, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
4 400,00 IU versus placebo
Ayah 2007 75 1.08 (0.31) 66 1.02 (0.17) 100.0 % 0.06 [ -0.02, 0.14 ]
Subtotal (95% CI) 75 66 100.0 % 0.06 [ -0.02, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.37, df = 3 (P = 0.95), I2 =0.0%
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Analysis 1.34. Comparison 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to
400,000 IU versus control (placebo, no treatment, other), Outcome 34 Infant low hepatic vitamin A reserves
at 6 - 6.5 months postpartum.
Review: Vitamin A supplementation for postpartum women
Comparison: 1 Supplement (vitamin A as retinyl, water-miscible or beta-carotene) 200,000 to 400,000 IU versus control (placebo, no treatment, other)
Outcome: 34 Infant low hepatic vitamin A reserves at 6 - 6.5 months postpartum
Study or subgroup Supplement Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 200,000 - 400,000 IU versus placebo
Ayah 2007 77/96 71/93 45.2 % 1.05 [ 0.90, 1.22 ]
RETIBETA Project 60/69 33/35 49.8 % 0.92 [ 0.82, 1.04 ]
Stoltzfus 1993a 7/67 15/64 5.0 % 0.45 [ 0.19, 1.02 ]
Subtotal (95% CI) 232 192 100.0 % 0.94 [ 0.78, 1.15 ]
Total events: 144 (Supplement), 119 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.36, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 0.59 (P = 0.55)
2 200,000 - 300,000 IU versus placebo
RETIBETA Project 60/69 33/35 56.6 % 0.92 [ 0.82, 1.04 ]
Stoltzfus 1993a 7/67 15/64 43.4 % 0.45 [ 0.19, 1.02 ]
Subtotal (95% CI) 136 99 100.0 % 0.67 [ 0.22, 2.05 ]
Total events: 67 (Supplement), 48 (Placebo)
Heterogeneity: Tau2 = 0.57; Chi2 = 7.20, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.70 (P = 0.49)
3 400,000 IU versus placebo
Ayah 2007 77/96 71/93 100.0 % 1.05 [ 0.90, 1.22 ]
Subtotal (95% CI) 96 93 100.0 % 1.05 [ 0.90, 1.22 ]
Total events: 77 (Supplement), 71 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 Beta-carotene: 7.8 mg daily versus placebo
RETIBETA Project 58/69 33/35 100.0 % 0.89 [ 0.78, 1.02 ]
Subtotal (95% CI) 69 35 100.0 % 0.89 [ 0.78, 1.02 ]
Total events: 58 (Supplement), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 2.99, df = 3 (P = 0.39), I2 =0.0%
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Analysis 2.1. Comparison 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU, Outcome 1
Maternal serum retinol (mcmol/L).
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU
Outcome: 1 Maternal serum retinol (mcmol/L)
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400,000 IU versus 200,000 IU at 2 months postpartum
Darboe 2007 96 1.43 (0.44) 97 1.41 (0.4) 66.2 % 0.02 [ -0.10, 0.14 ]
Fernandes 2012 119 2.04 (0.67) 117 1.96 (0.63) 33.8 % 0.08 [ -0.09, 0.25 ]
Subtotal (95% CI) 215 214 100.0 % 0.04 [ -0.06, 0.14 ]
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 400,000 IU versus 200,000 IU at 4 months postpartum
Fernandes 2012 103 2.1 (0.71) 110 2.22 (0.55) 100.0 % -0.12 [ -0.29, 0.05 ]
Subtotal (95% CI) 103 110 100.0 % -0.12 [ -0.29, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
3 400,000 IU versus 200,000 IU at 6 months postpartum
Fernandes 2012 95 2.14 (0.57) 105 2.22 (0.55) 100.0 % -0.08 [ -0.24, 0.08 ]
Subtotal (95% CI) 95 105 100.0 % -0.08 [ -0.24, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 3.37, df = 2 (P = 0.19), I2 =41%
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Analysis 2.2. Comparison 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU, Outcome 2
Maternal breast milk retinol (mcmol/L).
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU
Outcome: 2 Maternal breast milk retinol (mcmol/L)
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400,000 IU versus 200,000 IU at 2 months postpartum
Darboe 2007 96 1.69 (0.79) 95 1.67 (0.67) 36.1 % 0.02 [ -0.19, 0.23 ]
Fernandes 2012 97 0.53 (0.51) 89 0.56 (0.57) 63.9 % -0.03 [ -0.19, 0.13 ]
Subtotal (95% CI) 193 184 100.0 % -0.01 [ -0.14, 0.11 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 400,000 IU versus 200,000 IU at 3 months postpartum
Darboe 2007 94 1.68 (0.79) 96 1.74 (0.78) 100.0 % -0.06 [ -0.28, 0.16 ]
Subtotal (95% CI) 94 96 100.0 % -0.06 [ -0.28, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
3 400,000 IU versus 200,000 IU at 4 months postpartum
Darboe 2007 95 1.54 (0.75) 97 1.55 (0.84) 20.6 % -0.01 [ -0.24, 0.22 ]
Fernandes 2012 81 0.37 (0.28) 75 0.4 (0.43) 79.4 % -0.03 [ -0.14, 0.08 ]
Subtotal (95% CI) 176 172 100.0 % -0.03 [ -0.13, 0.08 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
4 400,000 IU versus 200,000 IU at 6 months postpartum
Darboe 2007 96 1.56 (0.84) 96 1.47 (0.71) 100.0 % 0.09 [ -0.13, 0.31 ]
Subtotal (95% CI) 96 96 100.0 % 0.09 [ -0.13, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 1.07, df = 3 (P = 0.78), I2 =0.0%
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Analysis 2.3. Comparison 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU, Outcome 3
Maternal breast milk retinol (< 1.05 mcmol/L).
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU
Outcome: 3 Maternal breast milk retinol (< 1.05 mcmol/L)
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 400,000 IU versus 200,000 IU at 3 months postpartum
Darboe 2007 22/94 18/96 100.0 % 1.25 [ 0.72, 2.17 ]
Subtotal (95% CI) 94 96 100.0 % 1.25 [ 0.72, 2.17 ]
Total events: 22 (High dose), 18 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 400,000 IU versus 200,000 IU at 6 months postpartum
Darboe 2007 26/96 32/96 100.0 % 0.81 [ 0.53, 1.25 ]
Subtotal (95% CI) 96 96 100.0 % 0.81 [ 0.53, 1.25 ]
Total events: 26 (High dose), 32 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 1.43, df = 1 (P = 0.23), I2 =30%
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Analysis 2.4. Comparison 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU, Outcome 4
Infant serum retinol (mcmol/L ).
Review: Vitamin A supplementation for postpartum women
Comparison: 2 Supplement (vitamin A as retinyl) 400,000 IU versus 200,000 IU
Outcome: 4 Infant serum retinol (mcmol/L )
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 400,000 IU versus 200,000 IU at 2 months postpartum
Darboe 2007 63 0.74 (0.21) 71 0.72 (0.2) 84.1 % 0.02 [ -0.05, 0.09 ]
Fernandes 2012 114 1.18 (0.57) 114 1.22 (0.66) 15.9 % -0.04 [ -0.20, 0.12 ]
Subtotal (95% CI) 177 185 100.0 % 0.01 [ -0.05, 0.07 ]
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
2 400,000 IU versus 200,000 IU at 4 months postpartum
Fernandes 2012 93 1.48 (0.55) 99 1.51 (0.67) 100.0 % -0.03 [ -0.20, 0.14 ]
Subtotal (95% CI) 93 99 100.0 % -0.03 [ -0.20, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
3 400,000 IU versus 200,000 IU at 6 months postpartum
Fernandes 2012 92 1.51 (0.53) 81 1.57 (0.6) 100.0 % -0.06 [ -0.23, 0.11 ]
Subtotal (95% CI) 92 81 100.0 % -0.06 [ -0.23, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.70, df = 2 (P = 0.71), I2 =0.0%
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A P P E N D I C E S
Appendix 1. Additional search strategies
LILACS - Latin American and Caribbean Health Sciences by Bireme (1982 to December 2015)
#1: ((Pt ENSAIO CONTROLADO ALEATORIO OR Pt ENSAIO CLINICO CONTROLADO OR Mh ENSAIOS CONTRO-
LADOS ALEATORIOS OR Mh DISTRIBUICAO ALEATORIA OR Mh MÉTODO DUPLO-CEGO OR Mh MÉTODO SIM-
PLES-CEGO) AND NOT (Ct ANIMAIS AND NOT (Ct HUMANO AND Ct ANIMAIS)) OR (Pt ENSAIO CLÍNICO OR Ex
E05.318.760.535$) OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw
singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$
OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh PLACEBOS OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw
casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR (Mh PROJETOS DE PESQUISA) ANDNOT (Ct ANIMAIS ANDNOT
(Ct HUMANO AND Ct ANIMAIS)) OR (Ct ESTUDO COMPARATIVO OR Ex E05.337$ OR Mh SEGUIMENTOS OR Mh
ESTUDOS PROSPECTIVOS OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct ANIMAIS
AND NOT (Ct HUMANO AND Ct ANIMAIS))) AND NOTMh ANIMAIS [Palavras]
#2: retinol or “vitamin A” or caroten$ [Palavras]
#3: #1 AND #2
WEB OF SCIENCE by ISI (1945 to December 2015)
#1: TS=(randomised controlled trial) OR TS=(controlled clinical trial) OR TS=(randomised controlled trials) OR TS=(random allo-
cation) OR TS=(double-blind method) OR TS=(single-blind method) OR TS=(clinical trial) OR TS=(clinical trials) OR TS=(clinical
trial) OR ((TS=singl* OR TS=doubl* OR TS=trebl* OR TS=tripl*) AND (TS=mask* OR TS=blind*)) OR (TS=(latin square) OR
TS=placebo* OR TS=random* OR TS=(research design) or TS=(comparative study) OR TS=(evaluation studies) OR TS=(follow-up
studies) OR TS=(prospective studies) OR TS=(cross-over studies) OR TS=control* OR TS=prospectiv* OR TS=volunteer*)
#2: TS=puerp* or TS=matern* or TS=lacta* or TS=breastfe* or TS=(breast fee*) or TS=breast-fee* or TS=(humanmilk) or TS=postnatal
or TS=postpart* or TS=newborn* or TS=infant* or TS=newborn
#3: TS=retinol* or TS=(vitamin A) or TS=caroten*
#4: #3 AND #2 AND #1
WH A T ’ S N E W
Date Event Description
28 April 2016 Amended The text in the results section on selection bias has been corrected
H I S T O R Y
Date Event Description
15 February 2016 New citation required but conclusions have not
changed
Search updated and two new studies have been in-
cluded in this reviewupdate (Fernandes 2012;Martins
2010).
15 February 2016 New search has been performed A new search was conducted. The addition of two
studies in the 2016 update of this review did notmean-
ingfully change the conclusions of the original review
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(Continued)
(Oliveira-Menegozzo 2010).
22 September 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
JM Oliveira, R Allert (new to the authorship for the 2016 update) and CE East updated this review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Cochrane Editorial Unit, UK.
The Cochrane Editorial Unit, Cochrane Central Executive (Toby Lasserson, Newton Opiyo) assisted in the use of GRADE and in the
development of the ’Summary of findings’ table.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Considerable collaborative input from referees, authors and other Cochrane personnel during preparation of the original review resulted
in a focus specifically on postpartum supplementation, rather than widening to include long-term supplementation during women’s
reproductive years or of infant supplementation (these were covered by separate reviews). At that time, we also added the potential for
including cluster-randomised trials, which were considered important for the purpose of the review, although none were ultimately
included.
In the 2016 update, we have edited the methods to incorporate changes over time to the methodology of the Pregnancy and Chidlbirth
Group. Specifically, and to avoid double counting, we adjusted the numbers of events (dichotomous outcomes) and total numbers
(continuous or dichotomous outcomes) contributing to the control group of the RETIBETA Project, as there were two comparisons
made with different forms of vitamin A supplementation.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Postpartum Period; Infant Mortality; Maternal Mortality; Milk, Human [chemistry]; Randomized Controlled Trials as Topic; Vitamin
A [∗administration & dosage; analysis]; Vitamin A Deficiency [drug therapy]; Vitamins [∗administration & dosage]
MeSH check words
Female; Humans; Infant; Infant, Newborn; Pregnancy
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